

CURRICULUM VITAE

PART I: General Information

DATE PREPARED: April 2015

Name: Santosh Kesari

Office Address: University of California, San Diego
Moore's Cancer Center
3855 Health Sciences Drive, MC 0819
La Jolla, CA 92093-0819
Phone: (858) 822-6346
Fax: (858) 822-7525

Work Email: skesari@ucsd.edu

Place of Birth: Hyderabad, India

Citizenship: USA

Education:

1989 H.S., George Washington High School
Charleston, WV

1989-1992 B.A., Biology and Mathematics
University of Pennsylvania, College of Arts and Sciences
Philadelphia, Pennsylvania

1992-1999 M.D., Medicine
University of Pennsylvania, School of Medicine

1993-1996 Ph.D., Molecular Biology
University of Pennsylvania, School of Medicine

Postdoctoral Training:

1999 Extern, Neurology
National Hospital for Neurology and Neurosurgery, Queen Square,
United Kingdom

1999-2000 Intern, Internal Medicine
Beth Israel Deaconess Medical Center, West Roxbury VA Hospital,
Boston, Massachusetts

2000-2003 Resident, Neurology, Partners Neurology Program

Massachusetts General Hospital, Brigham and Women's Hospital, Children's Hospital Boston, Jamaica Plain VA Hospital, Harvard Medical School, Boston, Massachusetts

- 2003-2004 Clinical Fellow, Neuro-Oncology, Mentors: Patrick Y. Wen and Tracey T. Batchelor, Dana-Farber Cancer Institute/Massachusetts General Hospital/Brigham and Women's Hospital, Boston, Massachusetts
- 2004 Program in Clinical Effectiveness
Harvard School of Public Health, Boston, Massachusetts
- 2004-2006 Research Fellow, Laboratory of Charles D. Stiles
Department of Cancer Biology, Dana-Farber Cancer Institute
- 2012-2013 Health Sciences Leadership Academy
UC San Diego, La Jolla, California

Licensure and Certification:

- 1999-2000 Limited License in Medicine
2000-2001 Limited License in Neurology
2001-2009 Full License in Massachusetts, inactive
2005-present American Board of Psychiatry and Neurology
2009-present Full License in California, active
2011-present Neuro-Oncology Certification, United Council for Neurologic Subspecialties
2013-present Fellow of the American Neurological Association
2013 Certificate in Healthcare Leadership, UC San Diego Extension

Academic Appointments:

- 1999-2000 Clinical Fellow in Medicine, Harvard Medical School
2000-2003 Clinical Fellow in Neurology, Harvard Medical School
2003-2007 Instructor in Neurology, Harvard Medical School
2007-2009 Assistant Professor in Neurology, Harvard Medical School
2009-2011 Visiting Associate Professor in Neurology, Harvard Medical School
2009-2013 Associate Professor in Neurosciences, UC San Diego
2013-present Professor in Neurosciences, UC San Diego
2013-present Adjunct Professor, Graduate School of Public Health, San Diego State University
2013-present Adjunct Professor in Radiation Medicine and Applied Sciences, UC San Diego

Hospital or Affiliated Institution Appointments:

- 1999-2000 Intern in Medicine, Beth Israel Deaconess Medical Center

2000-2003	Resident in Neurology, Partners Neurology Program, Massachusetts General Hospital, Brigham and Women's Hospital, Children's Hospital Boston
2003-2006	Fellow in Neuro-Oncology, Massachusetts General Hospital
2003-2009	Associate Physician, Dana-Farber Cancer Institute
2003-2009	Associate Physician, Brigham and Women's Hospital
2009-2011	Visiting Scientist in Medical Oncology, Dana-Farber Cancer Institute
2009-present	Attending Physician, UC San Diego Medical Center

Hospital and Health Care Organization Service Responsibilities:

1999-2000	Intern in Medicine, Beth Israel Deaconess Medical Center
2000-2003	Resident in Neurology, Partners Neurology Program, Massachusetts General Hospital, Brigham and Women's Hospital, Children's Hospital Boston
2003-2006	Fellow in Neuro-Oncology, Massachusetts General Hospital
2003-2009	Member, Harvard Center for Neurodegeneration and Repair
2003-2009	Attending Physician, Dana-Farber Cancer Institute
2003-2009	Attending Physician, Brigham and Women's Hospital
2005-2009	Member, Dana-Farber/Harvard Cancer Center
2007-2009	Affiliate Member, Harvard Stem Cell Institute
2007-2009	Harvard University NeuroScience (HUNS) Faculty

Major Administrative Responsibilities:

Brigham and Women's Hospital/Dana-Farber Cancer Institute

2002	Chair, Information Technology Committee, Partners Neurology Residency Program
2003-2009	Member, weekly Brain Tumor Center Conference, Dana-Farber/Brigham and Women's Cancer Center
2003-2007	Organizer, weekly Neuro-Oncology Conference at Dana-Farber/Brigham and Women's Cancer Center
2007-2009	Co-organizer, weekly Neuro-Oncology Conference at Dana-Farber/Brigham and Women's Cancer Center

UC San Diego, School of Medicine

2009-present	Chief, Division of Neuro-Oncology, Department of Neurosciences, UC San Diego
2009-present	Director, Neuro-Oncology Program, UC San Diego Moores Cancer Center
2009-present	Organizer, weekly Neuro-Oncology Conference at UC San Diego Moores Cancer Center
2009-present	Organizer, weekly Brain Tumor Board at UC San Diego Moores Cancer Center
2010-present	Co-Leader, CNS Specialized Cancer Unit, Moores Cancer Center
2010-present	Director, Neuro-Oncology Fellowship Program, UC San Diego

- 2010-present Moores Cancer Center
Organizer, Brain Tumors: Annual Collaborative Care Conference, UC
San Diego School of Medicine
- 2013-present Organizer, weekly Clinical Trial Research Coordinator (CTRC)
Rounds at UC San Diego Moores Cancer Center

Major Committee Assignments:

Brigham and Women's Hospital

- 2005-2006 Member, Neuroscience Database Working Group, Brigham and
Women's Hospital, Biomedical Research Institute
- 2006-2007 Member, Neuroscience Working Group, Neuroscience Comprehensive
Research Center, Brigham and Women's Hospital, Biomedical
Research Institute
- 2006-2007 Member, Fund Raising Task Force, Neuroscience Comprehensive
Research Center, Brigham and Women's Hospital, Biomedical
Research Institute

UC San Diego, School of Medicine

- 2010-present Associate Member, Clinical and Translational Research Institute
- 2011-present Speakers Bureau, UC San Diego Health Sciences Government and
Community Affairs Department
- 2012-present Member, Recruitment and Admissions Committee, UC San Diego
- 2014-present Member, Scientific Review Committee, Clinical Translational
Research Institute (CTRI) Pilot Project Grants Program
- 2014-present Member, Cancer Center Global Health, Division Chief of Global
Health at the Department of Family & Preventive Medicine

UC San Diego, Department of Neurosciences

- 2010-2012 Member, Academic Faculty Senate representative assembly
- 2010-present Member, Clinical Practice committee
- 2010-present Member, Research committee
- 2011-2012 Chair, Clinical Neuro-Oncology Faculty Search Committee
- 2011-2012 Chair, Research Neuro-Oncology Faculty Search Committee
- 2012-present Member, Ad Hoc Committee Reviewer, Neurosciences Committee on
Academic Promotions
- 2014-present Member, Neurological Council Workgroup

UC San Diego, Moores Cancer Center

- 2010 Member, Retreat planning committee, Moores Cancer Center 2011
Scientific Faculty Retreat
- 2010 Member, Clinical Interface Team, Program in Translational and
Clinical Cancer Genomics, Moores Cancer Center
- 2010 Member, Drug Discovery Interest Group, Moores Cancer Center

2010-present	Member, Moores UCSD Cancer Center Cabinet Leadership Steering Committee
2011-2014	Member, Oncology Research Group (ORG) committee, Moores Cancer Center
2011	Member, Retreat planning committee, Moores Cancer Center 2012 Scientific Faculty Retreat “Transdisciplinary Research”
2012-2014	Member, Quality Committee, Moores Cancer Center
2013	Member, Scientific Review Committee, MCC CCSG pilot project grant, Moores Cancer Center
2014-2017	Member, Scientific Review Committee, ACS-IRG pilot project grant, Moores Cancer Center

UC San Diego, Department of Pathology

2011	Member, Neuropathology Faculty Search Committee
------	---

National

2006-present	International Outreach Committee, Society for Neuro-Oncology
--------------	--

International

2009-present	Advisor, Indian Society for Neuro-Oncology Annual Meeting, India
2014	Scientific Review Committee, 11 th Meeting of the Asian Society Neuro-Oncology, Istanbul, Turkey

Community Service Related to Professional Work:

2007	Speaker, “Asian Staff and Faculty at DFCI: Who are we?” Asian Pacific American Heritage Month, DFCI Cultural Observances Committee, Boston, MA
2007	Speaker, Continuing Umbrella of Research Experiences (CURE) Summer student training program, DFCI, Boston, MA
2007	Health Screener, India Day Health Screening Fair IMANE (Indian Medical Association of New England)
2007	Panelist, Cultural Cross Panel Dialogue, “Communicating Across Cultures” Course for Masters Program, Simmons College, Boston, MA
2010	Keynote Speaker, San Diego Brain Tumor Foundation, Open House at Moores Cancer Center, “Accelerating Novel Treatment Strategies for Brain Tumors”
2010	Speaker, Moose Lodge #1713, Monthly San Diego District Meeting, Lemon Grove, CA, “Advances in Cancer Treatments”
2010	Speaker, Patient and Family Resource Center at Moores Cancer Center, “Overview of the new Brain Cancer Unit and the basics of brain cancer, treatments and psychosocial effects of the disease” La Jolla, CA

2010	Speaker, Visiting Dokkyo medical students, Moores Cancer Center, “Overview of Neuro-Oncology” La Jolla, CA
2011	Speaker, Encinitas community, Encinitas Library, Spotlight on Cancer series, “Brain Tumors: Causes, hereditary factors, and treatment options” Encinitas, CA
2011	Consultant and Physician Champion for the Philippine Nurses Association’s Cancer Survivors Network, San Diego, CA
2011	Speaker, Rady’s Children’s Hospital Neuro-Oncology Family Day, San Diego, CA
2011-present	Host Committee for Innovation Night at the La Jolla Playhouse, La Jolla, CA
2012	Speaker, Rady’s Children’s Hospital Neuro-Oncology Family Day, San Diego, CA
2013	Speaker, NF California, “Ask the Doctor” event, La Jolla, CA
2014	Mentor, Doctor Mentorship Program, Phi Delta Epsilon International Medical Fraternity, UC San Diego, La Jolla, CA
2014	Speaker, NF California and Children’s Tumor Foundation, “Ask the Doctor” meeting, La Jolla, CA
2014	Speaker, Rady’s Children’s Hospital Neuro-Oncology Family Day, San Diego, CA

Professional Societies:

1994-present	Society for Neuroscience	Member
1995-present	American Assoc. for the Advancement of Science	Member
1999-2010	Massachusetts Medical Society	Member
2000-2010	Boston Society of Neurology and Psychiatry	Member
2000-present	American Academy of Neurology	Member
2002-present	Society for Neuro-Oncology	Member
2004-present	American Society of Clinical Oncology	Member
2006-2009	New York Academy of Sciences	Member
2007-present	AANS/CNS Section on Tumors	Member
2007-2009	Brain Research Academy International for Neoplasia (B.R.A.I.N.)	Founding Member
2007-present	Association of Indian Neurologists in America	Member
2007-2009	Center for the Development of a Virtual Tumor (CViT)	Member
2008-present	American Association for Cancer Research	Member
2008-present	European Association of Neuro-Oncology	Member
2008-present	American Society of Neuroimaging	Member
2009-present	Indian Society of Neuro-Oncology	Member
2010-present	Association of California Neurologists	Member
2013-present	American Neurological Association	Member

Editorial Boards:

2003-present	Ad-hoc Reviewer	Cancer Investigation
2004-present	Ad-hoc Reviewer	Neurology

2004-present	Ad-hoc Reviewer	Neurology India
2004-2005	Ad-hoc Reviewer	Journal of Neuro-Oncology
2004-present	Ad-hoc Reviewer	Journal of Neuroimaging
2005-present	Ad-hoc Reviewer	Journal of Clinical Oncology
2005-present	Editorial Board	Journal of Neuro-Oncology
2006-present	Ad-hoc Reviewer	Expert Review of Anticancer Therapy
2006-present	Ad-hoc Reviewer	Stem Cells
2007-present	Ad-hoc Reviewer	Biologics: Targets & Therapy
2007-present	Ad-hoc Reviewer	Targeted Proteins Database (TPdb)
2007-present	Ad-hoc Reviewer	Journal of the Neurological Sciences
2007-present	Ad-hoc Reviewer	Breast Cancer Research
2007-present	Ad-hoc Reviewer	Cancer
2007-present	Ad-hoc Reviewer	New England Journal of Medicine
2008-present	Editorial Board (Founding)	International Journal of Biomedical Nanoscience and Nanotechnology
2008-present	Ad-hoc Reviewer	Future Neurology
2008-present	Ad-hoc Reviewer	Cancer Chemotherapy and Pharmacology
2008-present	Ad-hoc Reviewer	Acta Neuropathologica
2008-present	Ad-hoc Reviewer	Brain Research
2008-present	Ad-hoc Reviewer	Molecular Cancer Therapeutics
2008-present	Ad-hoc Reviewer	NeuroImage
2008-present	Ad-hoc Reviewer	Wiener klinische Wochenschrift
2008-present	Ad-hoc Reviewer	Journal of Neurology, Neurosurgery & Psychiatry
2008-present	Ad-hoc Reviewer	Transplant Infectious Disease
2009-present	Ad-hoc Reviewer	Journal of Clinical Neurology
2009-present	Ad-hoc Reviewer	Cancer Research
2009-present	Ad-hoc Reviewer	Hospital Physician
2009-present	Ad-hoc Reviewer	Cancer Letters
2009-present	Ad-hoc Reviewer	Journal of Clinical Investigation
2009-present	Ad-hoc Reviewer	Radiotherapy and Oncology
2009-present	Ad-hoc Reviewer	Neuro-Oncology
2010-present	Ad-hoc Reviewer	Nature Reviews Clinical Oncology
2010-present	Ad-hoc Reviewer	Brain
2010-present	Ad-hoc Reviewer	International Journal of Cancer
2010-present	Ad-hoc Reviewer	Cancer Biology and Therapy
2010-present	Ad-hoc Reviewer	Laboratory Investigation
2010-present	Ad-hoc Reviewer	Journal of Clinical Oncology
2010-present	Ad-hoc Reviewer	PLoS ONE
2010-present	Ad-hoc Reviewer	Drugs of Today
2010-present	Ad-hoc Reviewer	Webmedcentral
2011-present	Ad-hoc Reviewer	Neurosurgery
2011-present	Ad-hoc Reviewer	Journal of the Royal Society Interface
2011-present	Ad-hoc Reviewer	International Journal of Biomedical Science
2011-present	Ad-hoc Reviewer	Clinical Investigation
2011-present	Ad-hoc Reviewer	Proceedings of the National Academy of

		Sciences
2011-present	Ad-hoc Reviewer	Experimental Neurology
2011-present	Ad-hoc Reviewer	Glia
2011-present	Ad-hoc Reviewer	BBA - Reviews on Cancer
2011-present	Editorial Board (Founding)	CNS Oncology
2011-present	Ad-hoc Reviewer	Journal of Hematology & Oncology
2012-present	Ad-hoc Reviewer	Clinical Cancer Research
2012-present	Senior Editorial Board	American Journal of Cancer Research
2012-present	Ad-hoc Reviewer	European Journal of Medical Research
2012-present	Ad-hoc Reviewer	Genes, Chromosomes and Cancer
2012-present	Ad-hoc Reviewer	European Journal of Cancer
2012-present	Ad-hoc Reviewer	Tumori
2012-present	Ad-hoc Reviewer	F1000 Medicine Reports
2012-present	Editorial Board	Translational Neuroscience
2012-present	Ad-hoc Reviewer	Expert Opinion On Investigational Drugs
2012-present	Ad-hoc Reviewer	Science Translational Medicine
2012-present	Editorial Board	Neuroscience Journal
2012-present	Ad-hoc Reviewer	Clinical Neurology and Neurosurgery
2012-present	Ad-hoc Reviewer	Journal of Clinical Investigation
2012-present	Editorial Board	Open Journal of Regenerative Medicine
2012-present	Ad-hoc Reviewer	Clinical Chemistry
2012-present	Ad-hoc Reviewer	Canadian Journal of Neurological Sciences
2012-present	Ad-hoc Reviewer	International Journal of Molecular Sciences
2012-present	Ad-hoc Reviewer	Molecular Biosystems
2012-present	Ad-hoc Reviewer	Metabolic Brain Disease
2013-present	Ad-hoc Reviewer	BioMedCentral
2013-present	Editorial Board	Journal of Neurological Sciences
2013-present	Editorial Board	Journal of Translational Medicine
2013-present	Editorial Board	Journal of Tumor
2013-present	Editorial Board	Middle East Journal of Cancer
2013-present	Ad-hoc Reviewer	African Journal of Biotechnology
2013-present	Ad-hoc Reviewer	Nanomedicine
2013-present	Ad-hoc Reviewer	Cell Cycle
2013-present	Editorial Board	Nature Scientific Reports
2013-present	Ad-hoc Reviewer	Journal of Neuroimaging
2013-present	Ad-hoc Reviewer	Future Oncology
2014-present	Ad-hoc Reviewer	Oncogene
2014-present	Section Review Editor	Frontiers in Radiation and Health, Frontiers in Public Health
2014-present	Ad-hoc Reviewer	Pharmaceutical Research
2014-present	Ad-hoc Reviewer	Molecular Cancer
2014-present	Ad-hoc Reviewer	Advances in Pharmacology
2014-present	Ad-hoc Reviewer	Clinical Breast Cancer
2014-present	Editorial Board (Founding)	Scholarena Journal of Neurology
2014-present	Ad-hoc Reviewer	Journal of Neurochemistry

2014-present	Ad-hoc Reviewer	Muscle and Nerve
2014-present	Editorial Board (Founding)	Molecular Inhibitors in Targeted Therapy
2014-present	Ad-hoc Reviewer	Cancer Informatics
2014-present	Editorial Board	C21 Healthcare, Inc
2014-present	Ad-hoc Reviewer	Libertas Academica
2015-present	Ad-hoc Reviewer	Clinical & Experimental Metastasis
2015-present	Ad-hoc Reviewer	Medical Hypothesis
2015-present	Editorial Board	Annals of Translational Medicine

Grant Reviews:

2004	External Grant Reviewer	Catalan Agency for Health Technology Assessment and Research (CAHTA), Barcelona, Spain
2006	External Grant Reviewer	Children's Brain Tumor Foundation (CBTF), New York, NY
2008	Ad Hoc Member	NIH-RAID Study Section (X01), ZRG1 BST-J (90) R, Special Emphasis Review Panel, National Institutes of Health, Bethesda, MD
2009	External Grant Reviewer	Ontario Ministry of Research and Innovation, Ontario Research Fund - Global Leadership Round in Genomics & Life Sciences Competition (GL2 Competition), Ontario, Canada
2010	Ivy Scientific Reviewer Network (SRN)	The Ben and Catherine Ivy Foundation
2010	Grant Reviewer	Center for Integration of Medicine and Innovative Technology, HMS, Boston, U54 center grant, Bioengineering and Bioinformatics Program, The Methodist Hospital Research Institute
2010	Grant Reviewer	Estonian Science Foundation
2010	Grant Reviewer	American Brain Tumor Association
2010-present	Grant Reviewer	Cancer Research UK
2011	Grant Reviewer	Istituto Toscano Tumori (ITT), Florence, Italy
2012	Grant Reviewer	Archimedes Foundation, Tartu, Estonia Foundation
2012	Grant Reviewer	CTEP/NCI grant reviewer, Adult Brain Tumor Consortium Reviewer
2012	Grant Reviewer	NIH, NCI Subcommittee J, ad hoc
2012-2013	Blinded Clinical Reviewer	RadMD, ICON Medical Imaging
2013	PO1 External Advisor	Dr. Joe Ramos, University of Hawaii Cancer Center
2013-present	Grant Reviewer	Voices Against Brain Cancer Foundation
2013	External Grant Reviewer	Catalan Agency for Health Information,

		Assessment and Quality (CAHIAQ), TV3 Marató Call about Cancer Barcelona, Spain
2013	NCI Site Visit Reviewer	NIH, CABSC, NCI Intramural Program Radiation Oncology Branch (ROB)
2013-present	Grant Reviewer	NIH, NCI Subcommittee J, standing
2013	Grant Reviewer	Medical Research Council (MRC), London, United Kingdom
2013	Grant Reviewer	Institute of Translational Science at the Brain and Spine Institute (IHU-A-ICM), Hôpital Pitié-Salpêtrière, Paris, France
2014	Abstract Review Committee	Preclinical Experimental Therapeutics; 20th International Conference on Brain Tumor Research and Therapy (ICBRT20), Lake Tahoe, California
2014	Grant Reviewer	National Science Centre (Narodowe Centrum Nauki – NCN), Poland
2014	Grant Reviewer	Health Research Board, Ireland
2014	Grant Reviewer	Oak Ridge Associated Universities
2014	Final Performance Reviewer	Master Tobacco Settlement Fund, Pennsylvania Department of Health
2014	Grant Reviewer	Swiss National Science Foundation
2014	Grant Reviewer	Cancer Research UK, London, UK
2014	Grant Reviewer	Swiss Cancer League
2014	Grant Reviewer	Nazarbayev University Cancer Research
2014	Grant Reviewer	BlastGBM Foundation, Ohio
2015	Grant Reviewer	NIH, NCI Outstanding Investigators Award study section

Awards and Honors:

1988	United States Academic Decathlon Participant
1990	Penn Medical Scholar, University of Pennsylvania
1991	Benjamin Franklin Scholar, University of Pennsylvania
1991	Pi Mu Epsilon National Mathematics Honor Society
1994	NIH National Research Service Award
1995	American Society for Virology Student Travel Award
1995	Dr. William A. Jeffers Prize, University of Pennsylvania
1996	Dr. William A. Jeffers Prize, University of Pennsylvania
2002	American Neurological Association Travel Award
2003	Founders Award, American Academy of Neurology
2006	Sontag Foundation Distinguished Scientist Award
2007-2009	Marquis Who's Who in America
2008	Marquis Who's Who in Science and Engineering
2008	Global Directory of Who's Who
2009	Gold Doc Award, Arnold P. Gold Foundation
2010	Overseas Executive Chairman, Chongqing International Neurological

Forum, Chongqing Association for Science and Technology,
Chongqing, China
2010-present Best Doctors in America
2011 U.S. News Top Doctors in Medical Oncology
2011 Doc Star (Cancer), Geoffrey Beene Rock Stars of Science
2011 Finalist, Health Care Champions Award, Health Technology
Innovations and Research, San Diego Business Journal
2011 Special Commendation from Mayor Jerry Sanders, City of San Diego
2011 Certificate of Appreciation from Pam Slater-Price, County of San
Diego
2012 Recipient, UC San Diego CARES (Clinical Advancement &
Recognition of Excellence in Service)
2012 Castle Connolly Top Doctors: Southern California
2012 Winner, Innovation Awards, Medical Research, San Diego Business
Journal
2013 Recipient, UC San Diego CARES (Clinical Advancement &
Recognition of Excellence in Service)
2015 UCSD Health Sciences Academy of Clinician Scholars

Medical/Scientific Advisory Boards:

2009-present Kenney/Quinn/Ford Brain Tumor Research Foundation
2009-present Advisor, Indian Society for Neuro-Oncology
2010 Children's Tumor Foundation NF1 Think Tank meeting
2010-present Indian Society of Neuro-Oncology, International Advisory Board
2010-present American Brain Tumor Association, Scientific Advisory Council
2010-present San Diego Brain Tumor Foundation, Medical Advisory Council
2010-present Global Cures, Inc, Scientific Advisor
2011-present Accelerate Brain Cancer Cure, Scientific Advisory Board
2012 Brain Tumors Funders Collaborative Advisory Board
2012-present The Elliott Foundation/Chris Elliott Fund, Medical Board
2012-present The Nicolas Conor Institute, Scientific Advisory Board
2012-present California Brain Tumor Association, Medical Advisory Board
2012-present Voices Against Brain Cancer, Medical Advisory Board
2012-present Philippine Brain Tumor Alliance, Board of Advisors
2014-present Blast Glioblastoma Foundation, Medical Advisory Board, Akron, OH

Biotechnology/Industry:

2012-present: DrugArray, Founder, SAB
2013-present: Curtana Pharmaceuticals, Founder, Board Member, SAB
2013-present: Brain Cancer Research Institute, SAB
2014-present: PrimeVax, Founder, Board Member, SAB
2014-present: Lemma Pharmaceuticals, Founder, Board Member, SAB
2014-present: Nascent Biotechnology, Member of SAB
2014-present: Pharmanostics, Founder, Board Member, SAB
2015-present: Batu Biologics, SAB
2015-present: Nativis, SAB

2015-present: Sefacor, Founder, Board Member, SAB
2015-present: Pharmanostics, Founder, Board Member, SAB
2015-present: Regen BioPharma Inc, SAB

Issued and Pending Patents:

- 1) Dayu Teng, Shu Chein, **Santosh Kesari**, Pengfei Jiang. Small Molecule Microarrays and Methods for Making and Using Them. UCSD SD2011-024, U.S. Provisional Patent 61/375,373, filed August 20, 2010. PCT: PCT/US2011/048395; WO/2012/024574 on Aug 19, 2011. 20130184179
- 2) Anna M. Krichevsky, Nadiya M Teplyuk, Brit Mollenhauer, **Santosh Kesari**. Diagnosing and Monitoring CNS Malignancies Using MicroRNA. UCSD SD2012-165-1/BWH 29618-0012P01, U.S. Provisional Application Serial No. 61/457,000, filed on November 10, 2010. PCT: PCT/US2011/061047; WO/2012/068288 on Nov 16, 2011. 20130344063
- 3) **Santosh Kesari**, Rajesh Mukthavaram, Milan Makale, Wolf Wrasidlo. Liposomal Encapsulation of Drugs. UCSD SD2012-176-1, U.S. Provisional Application Serial No. 61/569,146, filed on December 9, 2011. PCT: PCT/US2012/068813; WO/2013/086526. 20140356416
- 4) **Santosh Kesari**, Rajesh Mukthavaram, Igor Tsigelny, Milan Makale, Wolf Wrasidlo. Novel therapeutics for brain cancers. UCSD SD2011-212, U.S. Provisional Application Serial No. 61/660,631, filed on June 15, 2012.
- 5) Milan T. Makale, Wolfgang Wrasidlo, Joanna McKittrick, **Santosh Kesari**. UCSD Provisional patent application in progress. Wide Field Low Dose Irradiation To Activate an Anti-Tumor Pro-Drug Carried by a Nanovehicle. UCSD SD2013-199-1, U.S. Provisional Application Serial No. xxx, filed on September 15, 2013.
- 6) **Santosh Kesari**, Rajesh Mukthavaram, Milan Makale, Wolf Wrasidlo. Liposomal Staurosporine Encapsulation. UCSD SD2014-233, U.S. Provisional Application Serial No. xxx, filed on April 10, 2014.
- 7) Milan T. Makale, Wolfgang Wrasidlo, Joanna McKittrick, **Santosh Kesari**. Design and attachment of a photocleavable linker to a nanoscintillator crystal to enable the attachment and radiation induced release of drugs and other agents. UCSD SD2014-357, U.S. Provisional Application Serial No. xxx, filed on September 15, 2014.
- 8) Thomas Ichim, xxx, **Santosh Kesari**. Stimulation of Immunity to Endothelial Cells, Endothelial-like Cells, and Intratumor Vascular Channels Derived from Tumor Tissue. Batu Biologics filed January 2015
- 9) Thomas Ichim, xxx, **Santosh Kesari**. Composite Tissue Cancer Vaccine. Batu Biologics filed January 2015
- 10) Thomas Ichim, xxx, **Santosh Kesari**. Chimeric Antigen Receptor Dendritic Cell (CAR-DC) for Treatment of Cancer. Batu Biologics filed February 2015

Trademarks:

2010 Marlon Garzia Saria, **Santosh Kesari**
Mark: PERSONALIZED CARE IN THE ERA OF PERSONALIZED MEDICINE
Serial number: 85032415

PART II: Research, Teaching, and Clinical Contributions

A. Narrative Report

My research program is focused on understanding the developmental and molecular aberrations resulting in malignant gliomas and using this information to develop novel molecular therapeutics to improve the survival of my patients. Currently, I am the Director of Neuro-Oncology at the Moores UCSD Cancer Center and Chief of Division of Neuro-Oncology in the Department of Neurosciences. I spend 50% of my efforts in basic and translational research and 50% in clinical research and patient care.

In the lab my focus is on defining the role of Olig genes in the pathogenesis of gliomas, in particular, their role in maintaining the proliferative potential of glioma stem cells in mouse and human xenograft models. I am isolating glioma stem cells from fresh human surgical tissue and culturing *in vitro* and *in vivo* in mice to define the unique molecular and genetic biology of these cells in relation to the whole tumor. This will delineate a set of genes/pathways that is specific for glioma stem cells and lead to the development of small molecule inhibitors. We have also identified small molecule inhibitors of Olig2 pathway and these have been licensed out to a startup company.

The second major aspect of my research activities is in evaluating novel small molecular inhibitors of developmental pathways thought to be important in neural stem cells. In particular the Notch pathway has been shown to be important in gliomas and I have shown that a Notch pathway inhibitor can inhibit the growth of glioma stem cells. These preclinical studies have been quite promising and lead to Phase I/II trial of this gamma-secretase inhibitor in patients with recurrent malignant gliomas. I have also discovered a biomarker that is predictive of response to PDGFR kinase inhibitors and a phase II clinical trial in biomarker-enriched gliomas is in progress. These are some of the many prospective trials that are being planned for gliomas based on the laboratory discoveries. Additionally, combination therapy with multiple agents that target other developmental pathways and standard therapies (i.e, chemotherapy and radiation) may be more efficacious and are being explored in the lab.

My clinical work and teaching responsibilities also focus on neuro-oncological problems and lend insight into better ways to approach my research activities. I attend in the outpatient Neuro-Oncology Clinic two days per week where I care for patients with primary and metastatic brain tumors, paraneoplastic disorders, and neurological complications of cancer. Additionally, I care for patients admitted to the Thornton Hospital for neuro-oncological and medical issues. I also continue to teach medical students and residents as part of their core clinical neurology rotation. I am actively participating in the training of clinical fellows in medical oncology, neuro-oncology, and neurology.

B. Funding Information

Present:

2012-2017	NIH P32 Role: Co-Investigator (UCSD PI: Bob Carter) Experimental Therapeutics and Biomonitoring for Brain Tumors
2012-2015	Genelux

Role: Principal Investigator
Identification of CTCs in cancer patients

2013-2015 NIH R33
Role: Co-Investigator (PI: Dmitri Simberg, University of Colorado)
Microbubble technology to Isolate CTCs

2013-2015 NIH R33
Role: Co-Investigator (PI: Brunie Felding-Habermann, Scripps Research
Institute)
Metabolomic Analysis of Breast Cancer Progression

2014-2016 NIH R21
Role: Principal Investigator (Co-PI: Milan Makale)
A radiotherapeutic for breast cancer brain metastases

2014-2015 NIH STTR, Phase I
Role: Co-PI (Co-PI: Andy Haitt, Mapp Biopharmaceutical)
Novel Immunotherapy for Brain Cancer

2014-2015 NIH STTR, Phase I
Role: Co-PI (Co-PI: Greg Stein, Curtana Pharmaceuticals)
Validation of a Novel Treatment for Glioblastoma

2015 Nativis
Role: Principal Investigator
Cellular Effects of Radio Frequency Energy Therapy in Cancers

2015-2019 FDA R01
Role: Principal Investigator
Vascular-Targeted Prodrug for Recurrent Glioblastoma (IND #
105,830)

Pending:
2015 Cellworks
Role: Principal Investigator
Predictive in Silico Modeling to Identify Effective Therapeutics for
Glioblastoma

2015 Nascent Biotechnologies
Role: Principal Investigator
Pritumumab for GBM

2015 Batu Biologics
Role: Principal Investigator
ValloVax for GBM

2015 Nativis

- Role: Principal Investigator
Voyager device for intracranial GBM
- 2015-2020 NIH R01
Role: Co-Investigator (PI: Roland Friedel, Icahn School of Medicine at Mount-Sinai)
Plexin-B2 signaling in glioma growth, invasion, and glioma stem cell maintenance
- 2015-2018 American Cancer Society
Role: Co-Investigator (UCSD PI: Carrie McDonald)
Restriction Spectrum Imaging (RSI) for Detecting and Monitoring Brain Tumors
- 2015-2020 NIH R01
Role: Co-Investigator (PI: Zhihui Wang, University of New Mexico)
An Integrated Multiscale Systems Modeling Approach to Identifying Drug Targets and Optimizing Target Combinations for Glioblastoma
- 2015-2020 NIH R01
Role: Co-Investigator (PI: Joe Ramos, University of Hawaii)
RSK-2 regulates integrin-mediated adhesion and migration
- 2015-2018 NASA Step 2 Application
Role: Co-Investigator (UCSD PI: Brandon R. Macias)
Mitigating headward fluid shifts and vision impairment with thigh cuffs during spaceflight
- 2015-2019 FDA R01
Role: Co-Investigator (PI: Shama Mirza, Medical College of Wisconsin)
Identifying GBM Survival Pathways via Proteomics that Guide to New Drug Targets
- Past:**
- 1993-1994 Wistar Institute Taxin Brain Tumor Center Grant
Role: Co-Principal Investigator
Gene Therapy for Brain Tumors
- 1994 Wistar Institute Cancer Training Grant
Role: Co-Principal Investigator
HSV for Brain Tumors
- 1994 Medical Scientist Training Program
University of Pennsylvania, School of Medicine
Role: Fellowship (Declined)

- HSV for the treatment of brain tumors
- 1994-1999 National Research Service Award
NIMH/NIH
Role: Principal Investigator (\$)
Herpes Virus Therapy for Experimental Brain Tumors
- 2004-2006 NCI K12 Award: Clinical Research Training Program in Neuro-
Oncology
Role: Fellowship (\$)
Mentors: Patrick Y. Wen, Charles D. Stiles
- 2006-2007 Hagerty Award, Department of Neurosurgery, Brigham and Women's
Hospital
Role: Principal Investigator (\$)
Olig genes and role in human gliomas
- 2006-2007 Theodore Sapper/American Brain Tumor Association Grant
Role: Principal Investigator (\$)
RNAi inhibition of Olig genes in human gliomas
- 2006-2007 Accelerate Brain Cancer Cure Project Grant
Role: Principal Investigator (\$)
Notch inhibition in malignant gliomas
- 2006-2007 National Brain Tumor Foundation Oligodendroglioma Grant
Role: Principal Investigator (\$)
Targeting of Olig2 in oligodendrogliomas
- 2008 UCB Pharma
Role: Co-Principal Investigator
Co-PI: Jong Woo Lee, BWH
Efficacy of levetiracetam in brain tumor patients
- 2006-2009 Sontag Foundation Distinguished Scientist Grant
Role: Principal Investigator (\$)
An Olig2:P53 axis in glioblastoma
- 2008-2011 General Electric Healthcare
Role: Principal Investigator (\$)
Personalized Translational Platform for Biomarker Discovery in Brain
Tumors
- 2007-2012 Mentored Clinical Scientist Research Career Development Award
(K08), NCI (\$)
Role: Principal Investigator
Role of Olig genes in human gliomagenesis

- 2011-2012 National Brain Tumor Society, David Cook Chair of Research.
Role: Principal Investigator (\$92,000)
Development of an *in silico* systems biology approach to personalizing glioblastoma therapy
- 2011-2012 E-therapeutics (\$100,000)
- 2011-2013 Nativis (~\$350,000)
- 2008-2011 General Electric Healthcare
Role: Principal Investigator
Personalized Translational Platform for Biomarker Discovery in Brain Tumors
- 2007-2012 Mentored Clinical Scientist Research Career Development Award (K08), NCI
Role: Principal Investigator
Role of Olig genes in human gliomagenesis
- 2010-2011 ARRA (CCSG), NIH
Role: Principal Investigator
Early stage physician scientist recruitment supplement
- 2011-2012 National Brain Tumor Society, David Cook Chair of Research.
Role: Principal Investigator
Development of an *in silico* systems biology approach to personalizing glioblastoma therapy
- 2011-2013 American Brain Tumor Association
Role: CoPI (PI: Rajesh Mukthavarum)
Identification of Potential OLG2 Inhibitors for the treatment of Glioblastoma
- 2011-2013 E-therapeutics
Role: Principal Investigator
Mechanims of dexanabinol effects in glioblastoma
- 2011-2013 UC San Diego Moores Cancer Center Pilot Funding
Role: Principal Investigator
Companion study to identify biomarkers of response to notch inhibitors in human glioma clinical trials
- 2011-2013 Salk Institute Cancer Center Pilot Funding
Role: CoPI (PI: Inder Verma, Salk Institute)
Targeting TDECs in Human Glioblastomas
- 2009-2014 James S. McDonnell Foundation
Role: Principal Investigator

	Mechanisms of Sensitivity to PDGFR Inhibitors in Human Gliomas
2013-2014	Ambrx Inc. Role: Principal Investigator Anti-PSMA antibody-drug conjugate in glioblastoma
2013-2015	Voices Against Brain Cancer Role: Principal Investigator Development of GBM stem cell inhibitor
2013-2015	Voices Against Brain Cancer Role: Co-Investigator (UCSD PI: Milan Makale) A radiation activated prodrug-nanoparticle platform for brain cancer therapy
2014	Daisy Foundation Role: Co-Investigator (UCSD PI: Marlon Saria) An exploratory study of caregiver burden among caregivers of cancer patients with brain metastasis
2014	Ariad Pharmaceuticals Role: Principal Investigator Effect of Ponatinib on Glioblastoma
2014	E-therapeutics Role: Principal Investigator AntiCancer Effect of eTherapeutic compound in Gliomas
2014	Cellworks Role: Principal Investigator Predictive in Silico Modeling to Identify Effective Therapeutics for Glioblastoma
2014-2015	Kadmon Role: Principal Investigator KD019 – A Brain Penetrant Therapeutic For Glioblastoma

C. Report of Other Current Research Activities

Clinical Trials:

Principal Investigator

Dana-Farber Cancer Institute:

2007-2009	Phase 2, 2-Part, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of CT-322 (Angiocept™) Monotherapy and
-----------	--

Combination Therapy with Irinotecan in Patients with Recurrent Glioblastoma Multiforme
Sponsor: Adnexus Therapeutics, Inc.

2008-2009 Personalized Translational Platform for Biomarker Discovery in Brain Tumors
Sponsor: GE Healthcare (\$100,000)

UC San Diego:

2010-2011 Phase 2, 2-Part, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of CT-322 (Angiocept™) Monotherapy and Combination Therapy with Irinotecan in Patients with Recurrent Glioblastoma Multiforme
Sponsor: Adnexus Therapeutics, Inc./BMS(\$)

2010-2011 A Phase I Study of MK-0752, a Notch Inhibitor, in Patients with Metastatic or Locally Advanced Breast Cancer and Other Solid Tumors (Merck Protocol No. 014-07)
Sponsor: Merck (PI of the brain tumor component) (\$)

2010-2013 A Randomized Placebo-Controlled Trial of Armodafinil (Nuvigil®) for Fatigue in Patients with Malignant Gliomas Undergoing Radiotherapy with or without Standard Chemotherapy Treatment
Sponsor: Dana Farber/Aventis (\$)

2010-2012 Cilengitide in Subjects With Newly Diagnosed Glioblastoma Multiforme and Unmethylated MGMT Gene Promoter - a Multicenter, Open-label Phase II Study, Investigating Two Cilengitide Regimens in Combination With Standard Treatment (Temozolomide With Concomitant Radiation Therapy, Followed by Temozolomide Maintenance Therapy).
Sponsor: EMD-Serono(\$)

2010-2013 A Prospective, Multi-center Trial of NovoTTF-100A Together With Temozolomide Compared to Temozolomide Alone in Patients with Newly Diagnosed GBM (EF-14)
Sponsor: Novocure(\$)

2010-2010 Single Patient Emergency Use of NovoTTF-100A
Sponsor: Novocure(\$)

2010-2014 A Phase II Study of PDGFR Kinase Inhibitor in Biomarker-Enriched Recurrent Malignant Gliomas
Sponsor: UCSD/Novartis(\$)

- 2010-2014 CTSU E3F05: Phase III Study of Radiation Therapy with or without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas (E3F05)
Sponsor: CTUS/NCI/NIH(\$)
- 2011-2013 A Randomized, Double-blind, Controlled Phase IIb Study of the Safety and Efficacy of ICT-107 in Newly Diagnosed Patients With Glioblastoma Multiforme (GBM) Following Resection and Chemoradiation
Sponsor: ImmunoCellular Therapeutics (\$)
- 2011-2011 Compassionate Use of ICT-107 for a single patient
Sponsor: Immunocellular Therapeutics (\$)
- 2011-2013 A Phase I Ascending Dose Trial of the Safety and Tolerability of Toca 511 in Patients with Recurrent Glioblastoma Multiforme
Sponsor: Tocagen(\$)
- 2011-2013 Assessment of the Utility of the Radiotracer "FLT" in PET Imaging of de Novo Glioblastoma Multiforme (GBM): Monitoring Early Response to Chemotherapy
Sponsor: UCSD/Brigham & Women's Hospital(\$)
- 2011-2013 A Phase II, Multi-Center, Open-Label Study Evaluating GRN1005 Alone or in Combination with Trastuzumab in Breast Cancer Patients with Brain Metastases
Sponsor: Geron(\$)
- 2011-2013 A Phase II, Multi-Centre, Open-Label Study Evaluating the Efficacy and Safety of GRN1005 in Non-Small Cell Lung Cancer Patients with Brain Metastases
Sponsor: Geron(\$)
- 2011-2014 A Phase II Clinical Trial Evaluation DCVax®-Brain, Autologous Dendritic Cells Pulsed with Tumor Lysate Antigen for the Treatment of Glioblastoma Multiforme (GBM)
Sponsor: Northwest Biotherapeutics(\$)
- 2012-2013 A Phase I, Sequential Cohort, Open-Label, Dose-Escalation Study of the Safety and CNS Pharmacokinetics of Dexanabinol in Patients with Brain Cancer
Sponsor: UCSD/e-Therapeutics (\$)
- 2012-2013 A Phase 2 Study of LY2157299 Monohydrate Monotherapy or LY2157299 Monohydrate plus Lomustine Therapy compared to Lomustine Monotherapy in Patients with Recurrent Malignant Glioblastoma (JBAL)

	Sponsor: Eli Lilly (\$)
2012-2013	Phase 1b/2a Study Combining LY2157299 with Standard Temozolomide-based Radiochemotherapy in Patients with Newly Diagnosed Malignant Glioma (JBAI) Sponsor: Eli Lilly (\$)
2012-2014	A Continuation Protocol for Patients Previously Enrolled in a Study of Toca 511 Sponsor: Tocagen (\$)
2012-2013	Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined with Bevacizumab in Recurrent Glioblastoma (N0872) Sponsor: NCCTG/NCI/NIH (\$)
2012-present	A Prospective, non-randomized, concurrent control, open label, post-approval study of NovoTTF-100A in recurrent GBM patients (EF-19) Sponsor: Novocure (\$)
2012-present	An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF with Adjuvant Temozolomide in Patients with Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma (The ACT IV Study) Sponsor: Celldex (\$)
2012-2014	Expanded Access treatment use of mifepristone for an individual patient with meningioma Sponsor: In-House (\$)
2013-2014	A Phase 2 Study BrUOG 244, PPX and Concurrent Radiation for Newly Diagnosed GBM without MGMT Methylation Sponsor: BrUOG/CTI (\$)
2013-present	Initial Phase I Study of WT2725 Dosing Emulsion in Patients with Advanced Malignancies Sponsor: Sunovion (\$)
2013-present	N0577: Phase III Intergroup Study of Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma Sponsor: UCSD/ECOG (\$)
2014-present	A Phase II Study to Evaluate the Efficacy, Safety, and CNS Pharmacokinetics of the HER Family Inhibitor Dacomitinib in Progressive Brain Metastases Sponsor: UCSD/Pfizer (\$)

- 2014-present An Open-Label, Single-Arm, Phase II Study to Evaluate the Efficacy, Safety and CNS Exposure of G-202 in Patients with Recurrent or Progressive Glioblastoma
Sponsor: UCSD/Genspera (\$)
- 2014-present A Phase II, Open –Label, Multi-Center Study of Ang1005 in Participants with Recurrent High-Grade Gliomas
Sponsor: Angiochem (\$)
- 2014-present An exploratory study of caregiver burden among caregivers of cancer patients with brain metastasis.
Sponsor: In-House
Role: Co-Investigator, Co-PI: Marlon Saria
- 2014-present An exploratory study of caregiver burden among caregivers of cancer patients.
Sponsor: In-House
Role: Co-Investigator, Co-PI: Marlon Saria
- 2014-present A Phase II Study of NovoTTF-100A Alone and Combined with Temozolomide in Patients with Low-Grade Gliomas
Sponsor: UCSD/Novocure (\$)
- 2014-present A Phase I Dose Escalation and CNS Pharmacokinetic Study of Afatinib in Recurrent Gliomas and Brain Metastases
Sponsor: Boehringer Ingelheim (\$)
- 2014-present Alliance A221101: A Phase III Randomized, Double-Blind Placebo-Controlled Study of Armodafinil to Reduce Cancer-Related Fatigue in Patients with Glioblastoma Multiforme
- 2014-present ANG1005-CLN-04: A Phase II, Open-Label, Multi-Center Study of ANG1005 in HER2+ Breast Cancer Patients with Progressive/Recurrent Brain Metastases
Sponsor: Angiochem (\$)
- 2014-present A Phase 1b/2a Study of the Combination of KD019 and Trastuzumab in Subjects with HER-2-Positive Metastatic Breast Cancer
Sponsor: Kadmon (\$)

Co-Investigator

Dana-Farber Cancer Institute:

- 2003-2009 Phase II Trial of Oral Thalidomide, Celebrex, Etoposide, and Cytosin in Adult Patients with Relapsed or Progressive Malignant Glioma (01-278)

Sponsor: Schering-Plough/Celgene

- 2003-2009 A Phase II Open-Label Study of Oral, Continuous, Once Daily PTK787/ZK 222584 in Patients with Von Hippel-Lindau Disease (VHL) and Hemangioblastoma (HB) (02-103)
Sponsor: Novartis
- 2003-2009 Edotecarin vs Temozolomide or Carmustine (BCNU) or Lomustine (CCNU) in Patients with Glioblastoma Multiforme that has Progressed/Recurred after Alkylator-based (Neo)adjuvant Chemotherapy (03-205)
Sponsor: Pharmacia/Pfizer
- 2003-2009 ZD1839 Plus Temozolomide for Treatment of Malignant Brain Tumors (01-287)
Sponsor: NABTC/NCI/NIH
- 2003-2009 Phase I/II Trial of CCI-779 in Patients with Malignant Glioma (01-156)
Sponsor: NCI/CTEP/NABTC
- 2003-2009 Phase II Study of Temozolomide, Thalidomide and Celebrex in Patients with Newly Diagnosed Glioblastoma Multiforme in the Post Radiation Setting (00-302)
Sponsor: Schering-Plough/Celgene
- 2003-2009 CPT-11 and Temozolomide for Recurrent Glioma (00-269)
Sponsor: NABTC/NCI/NIH
- 2003-2009 A Phase I/II Trial of R115777 in Patients with Recurrent Malignant Glioma (00-015)
Sponsor: NABTC/NCI/NIH
- 2003-2009 A Phase II Study of Prolonged Daily Temozolomide for Low-Grade Glioma (01-111)
Sponsor: Schering-Plough
- 2003-2009 Phase II Trial of STI571 (NSC 716051) in Patients with Recurrent Meningioma (03-048)
Sponsor: NCI/NIH
- 2003-2009 A Phase I Trial of R115777 With Radiation Therapy and Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (02-247)
Sponsor: NABTC/NCI/NIH
- 2003-2009 A Phase I/II Trial of OSI-774 In Subjects with Recurrent Malignant Gliomas and Malignant Gliomas Post Radiation Therapy (02-171)

- Sponsor: NABTC/NCI/NIH
- 2003-2009 ZD1839 for Treatment of Recurrent or Progressive Malignant Astrocytoma or Glioblastoma and Recurrent or Progressive Meningioma: A Phase II Study with a Phase I Component for Patients Receiving EIAED's (01-221)
Sponsor: NABTC/NCI/NIH
- 2004-2009 A Biomarker and Phase II study of GW 572016 in Recurrent Malignant Glioma (04-428)
Sponsor: NABTC/NCI/NIH
- 2004-2009 Companion Pharmacokinetic Study to DFCI Protocol 04-428 (A Biomarker and Phase II study of GW572016 in Recurrent Malignant Glioma [NABTC 04-01]) (05-282)
Sponsor: GlaxoSmithKline, Inc
- 2004-2009 Phase II Trial of EMD 121974 for Recurrent Glioblastoma: A Clinical Trial with Tissue Correlates of Response (04-276)
Sponsor: NCI/NIH/NABTC
- 2004-2009 A Phase I/II Trial of Depsipeptide in Patients with Recurrent High Grade Gliomas (04-193)
Sponsor: NABTC/NCI/CTEP/NIH
- 2004-2009 A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Temozolomide or Placebo Added to Whole Brain Radiation Therapy for the Treatment of Brain Metastases from Non-Small Cell Lung Cancer (04-064)
Sponsor: Schering-Plough
- 2004-2009 A Phase III Randomized, Double-Blind Study Comparing Human Corticotropin-Releasing Factor (hCRF) to Placebo for Control of Symptoms Associated with Peritumoral Brain Edema in Patients with Malignant Brain Tumors Who Require Chronic Administration of High-Dose Dexamethasone (04-171)
Sponsor: Neurobiological Technologies, Inc.
- 2005-2009 Phase I Study of High Dose Gefitinib (Iressa) for the Treatment of Carcinomatous Meningitis in Adult Patients with Non-Small Cell Lung Cancer and Known or Suspected EGFR Mutations (05-403)
Sponsor: Astra Zeneca
- 2005-2009 An Open-label, Multi-Center, Phase II Study to Evaluate the Activity of Patupilone (EPO906), in the Treatment of Recurrent or Progressive Brain Metastases in Patients with Non-Small Cell Lung Cancer (05-393)
Sponsor: Novartis Pharmaceuticals Sponsored

- 2005-2009 A Phase I Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]) in Combination with Temozolomide in Patients with Malignant Gliomas (05-371)
Sponsor: NABTC/NCI/NIH
- 2005-2009 A Phase II Study of Rituximab and Temozolomide in Recurrent Primary CNS Lymphoma (05-325)
Sponsor: NABTC/NCI/NIH
- 2005-2009 A Phase I/II Study of Lenalidomide and Radiation Therapy in Patients with Newly-Diagnosed Glioblastoma (05-222)
Sponsor: Celgene Corporation
- 2005-2009 A Phase I/II Study of OSI-774 (Erlotinib) and CCI-779 (Temsirrolimus) in Patients with Recurrent Malignant Glioma (05-037)
Sponsor: NABTC/NCI/NIH
- 2005-2009 A Phase I Sequential Ascending Dose Trial of AP23573 in Patients with Progressive or Recurrent Malignant Glioma (05-035)
Sponsor: ARIAD, Inc.
- 2005-2009 A Phase II Study of Safety and Efficacy of Oral Gimatecan (ST1481) Administered to Patients with Glioblastoma Multiforme Cancer (05-291)
Sponsor: Sigma-Tau
- 2005-2009 A Phase II Study of AZD2171 in Recurrent Glioblastoma (05-254)
Sponsor: NCI
- 2005-2009 A Phase II Study of A Phase II Study of Rituximab and Temozolomide in Recurrent Primary CNS Lymphoma (05-325)
Sponsor: NABTC/NCI
- 2005-2009 Intensive Chemotherapy and Immunotherapy in Patients with Newly Diagnosed Primary CNS Lymphoma: CALGB 50202 (05-063)
Sponsor: CALGB/NCI
- 2006-2009 A Phase I Study of MK-0752, a Notch Inhibitor, in Patients with Metastatic or Locally Advanced Breast Cancer and other Solid Tumors (05-058)
Sponsor: Merck & Co., Inc
- 2006-2009 A Phase II, Multicenter, Randomized, Non-Comparative Clinical Trial to Evaluate the Efficacy and Safety of Bevacizumab Alone or in Combination with Irinotecan for Treatment of Glioblastoma Multiforme in First or Second Relapse (06-142)
Sponsor: Genentech, Inc

- 2006-2009 Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination with OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients with Recurrent Glioblastoma Multiforme or Gliosarcoma (06-101)
Sponsor: NABTC
- 2006-2009 A Randomized Phase 3 Study of Enzastaurin versus Lomustine in the Treatment of Recurrent, Intracranial Glioblastoma Multiforme (06-017)
Sponsor: Eli Lilly and Company
- 2006-2009 Phase II Single Arm Trial of VEGF Trap in Patients with Recurrent Temozolomide-Resistant Malignant Gliomas (06-266)
Sponsor: NABTC
- 2006-2009 Protocol AVF3708g: A Phase II, Multi-center, Randomized, Non-Comparative Clinical Trial to Evaluate the Efficacy and Safety of Bevacizumab Alone or in Combination with Irinotecan for Treatment of Glioblastoma Multiforme in First or Second Relapse (06-142)
Sponsor: Genentech
- 2006-2009 Phase I and Phase II, Open-Label, Multi-Center Trials of Pazopanib in Combination with Lapatinib in Adult Patients with Relapsed Malignant Glioma (06-220)
Sponsor: GlaxoSmithKline, Inc
- 2006-2009 A Phase II Study of Imatinib Mesylate plus Hydroxyurea in the Treatment of Patients with Recurrent/Progressive Meningioma (06-)
Sponsor: Novartis
- 2006- 2009 A Multicenter, Open-label, Single Agent, Two-stage Phase 2 Study to Evaluate the Efficacy and Safety of AMG 102 in Subjects with Advanced Malignant Glioma (06-215)
Sponsor: Amgen
- UC San Diego:*
- 2010-present Phase III Double-Blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide plus/minus Bevacizumab in Patients with Newly Diagnosed Glioblastoma (RTOG 0825)
Sponsor: RTOG/NCI/NIH
- 2012-present A Randomized Phase I/II Study of ABT-888 in Combination with Temozolomide in Recurrent (Temozolomide Resistant) Glioblastoma (RTOG 0929)
Sponsor: RTOG/NCI/NIH

- 2013-present A Phase III Trial of Post-Surgical Stereotactic Radiosurgery (SRS) Compared with Whole Brain Radiotherapy (WBRT) for Resected Metastatic Brain Disease (RTOG 1270)
Sponsor: RTOG/NCI/NIH
- 2013-present A Phase I, First-in-Human, Dose Escalation Trial of MSC2363318A, a Dual p70S6K/Akt Inhibitor, in Subjects with Advanced Malignancies
Sponsor: EMD Serono
- 2014-present N1174 Phase I/Comparative Randomized Phase II Trial of TRC105 plus Bevacizumab versus Bevacizumab in Bevacizumab-Naïve Patients with Recurrent Glioblastoma Multiforme
- 2014-present A Randomized Phase II Trial of Myeloablative versus Non-myeloablative Consolidation Chemotherapy for Newly Diagnosed Primary CNS B-cell Lymphoma (CALGB 51101)
PI: Wieduwilt

Other Research Studies:

Dana-Farber Cancer Institute:

- 2002-2009 Histological Studies of Progressive Multifocal Leukoencephalopathy (PML) (2002-P-000579)
Sponsor: In-House
Role: Co-Investigator
- 2003-2008 Validation of 1D, 2D, 3D and Volumetric Parameters in Neuroradiologic Response Assessment in Gliomas (03-260)
Sponsor: In-House
Role: Principal Investigator
- 2003-2008 Prognostic Factors in Adult Brainstem Gliomas (03-362)
Sponsor: In-House
Role: Principal Investigator
- 2003-2009 Analysis of the Hypercoagulable State Associated with Malignant Glioma (98-226)
Sponsor: In-House
Role: Co-Investigator
- 2003-2009 A Prospective National Study to Molecularly and Genetically Characterize Human Gliomas: The Glioma Molecular Diagnostic Initiative (03-021)
Sponsor: NABTC/NABTT/NCI/NIH
Role: Co-Investigator

- 2005-2008 A Prospective, Multinational, Multicenter, Double-Blind, Randomized, Active-Controlled Trial to Compare the Effects of Lotrel (Amlodipine/Benazepril) to Benazepril and Hydrochlorothiazide Combined on the Reduction of Cardiovascular Morbidity and Mortality in Patients with High Risk Hypertension: Avoiding Cardiovascular Events through COMbination Therapy in Patients Living with Systolic Hypertension (ACCOMPLISH)
Sponsor: Novartis
Role: Clinical Endpoint Committee Adjudicator for Stroke/TIA events
- 2005-2009` Validation Assay for MGMT Testing in Discarded Glioblastoma Multiforme Tumor Specimens (05-230)
Sponsor: BWH Pathology and Neurosurgery
Role: Co-Investigator
- 2005-2009 Companion Pharmacokinetic Study To DFCI Protocol 04-428: A Biomarker And Phase II Study of GW572016 in Recurrent Malignant Glioma (05-282)
Sponsor: GlaxoSmithKline, Inc
Role: Co-Investigator
- 2005-2009 Cellular Localization and Immune Response to JC Virus (2005-P-000300)
Sponsor: In-House
Role: Principal Investigator
- 2006- 2009 Outcomes of Patients with NF1 and Gliomas (2006-P-000422)
Sponsor: In-House
Role: Co-Investigator
- 2007- 2009 Retrospective Study To Evaluate the Pathology of Malignant Gliomas Treated With PDGFR Inhibitors
Sponsor: In-House
Role: Principal Investigator
- 2008- 2009 Ventricoperitoneal Shunt in Patients with Neurological Diseases (2008P-000301)
Sponsor: In-House
Role: Principal Investigator
- UC San Diego:*
- 2010-2013 Neurological Outcomes of Cancer (100936)
Sponsor: In-House
Role: Principal Investigator
- 2011-present A Retrospective Analysis of the Efficacy of Seizure Prophylaxis in Brain Tumors (110171)

	Sponsor: In-House Role: Principal Investigator
2011-present	Retrospective Analysis of Prognostic Factors in Cancer Patients with Neurological Diseases (110551) Sponsor: In-House Role: Principal Investigator
2012-2013	Cellular Localization and Immune Response in Progressive Multifocal Leukoencephalopathy (PML) Sponsor: In-House Role: Principal Investigator
2010-present	Investigation of factors that affect patterns of care and survival for brain and other central nervous system cancer patients throughout San Diego County and California. Sponsor: In-House Role: Principal Investigator
2012-present	Investigation of factors that affect outcomes in cancer patients throughout San Diego County and California. Sponsor: In-House Role: Principal Investigator
2013-present	UC San Diego Neurosurgery Operative Specimen Tissue Bank Sponsor: In-House Role: Co-Investigator

D. Report of Teaching

1. Local contributions

Invited teaching presentations:

2004	Invited Speaker, Neuro-Oncology Conference, Massachusetts General Hospital, Volumetric Analysis of Gliomas, Boston, Massachusetts (Neurologists, residents-8, 3 hours preparation, 1.5 hours contact)
2005	Invited Speaker, Neuro-Oncology Conference, Massachusetts General Hospital, Cancer Stem Cells in Gliomas, Boston, Massachusetts (Neurologists, residents-8, 3 hours preparation, 1.5 hours contact)
2006	Invited Speaker, Neuro-Oncology Conference, Massachusetts General Hospital, Role of Olig2 in Gliomagenesis, Boston, Massachusetts (Neurologists, residents-8, 3 hours preparation, 1 hour contact)
2006	Invited Speaker, Department of Medicine morning report for residents, Discussion of a patient with metastatic lung cancer and paraneoplastic opsoclonus-myoclonus syndrome (Medical residents-20, 3 hours preparation, 1.5 hour contact)

- 2007 Invited Speaker, Department of Medical Oncology, Brigham and Women's Hospital morning pathology conference for staff/fellows/residents, Discussion of a patient with atypical meningioma (Fellows-15, residents-10, 2 hour preparation, 1 hour contact)
- 2008 Invited Speaker, Partners Neurology Residency Program Neuroscience Seminar Series, Cancer Stem Cells and Role in Brain Tumors, (Residents-20, 3 hour preparation, 1 hour contact)
- 2008 Invited Speaker, Dana-Farber Cancer Institute Lymphoma Conference, Therapy considerations in lymphomatous meningitis (Physicians-5, nurses-10, 5 hour preparation, 1 hour contact)
- 2009 Invited Speaker, Brigham and Women's Hospital, Department of Neurology Neuroscience Seminar Series, Therapeutic advances in Neuro-Oncology (Physicians-15, medical students-7, 5 hour preparation, 1 hour contact)
- 2009 Invited Speaker, UCSD Neuro-Oncology Conference, Advances in Glioma Biology and Therapeutics (Physicians-6, 5 hour preparation, 1.5 hours contact)
- 2011 Invited Speaker, UCSD Hematology/Oncology Conference, Brain Tumors (Physicians-35, 5 hour preparation, 1.5 hours contact)
- 2012 Invited Speaker, Biomedical and Clinical Research Seminar, Identification of response biomarkers in glioblastoma (Physicians/scientists-20, 5 hour preparation, 1.5 hours contact)
- 2012 Invited Speaker, Geriatric Psychiatry Seminar, Neurology of Brain Tumors (Physicians-8, 3 hour preparation, 1.5 hours contact)
- 2012 Invited Speaker, Community Health Summer Program, UCSD, Brain Tumor, La Jolla, CA (Physicians-2, High School student ~40; 3 hour preparation, 1 hours contact)

Continuing medical education courses:

Harvard Medical School:

- 2004-2006 Lecturer, Neurology for Non-neurologist course (10 hours preparation, 1 hour contact per year)
- 2004-2006 Lecturer, Intensive Review of Neurology (16 hours preparation, 1 hour contact per year)
- 2005-2006 Lecturer, Tumors of the Central Nervous System (16 hours preparation, 1 hour contact per year)

UC San Diego:

- 2010 Facilitator, Small Literature Group, 12 students from medical and pharmacy school to review, present and discuss medical research papers to encourage critical thinking (30 hours preparation, 18hrs direct contact with student)
- 2011 Speaker, Brain Tumors: 1st Annual Collaborative Care Conference, Overview of Brain Tumors and Clinical Management

2011	Speaker, Brain Tumors: 1 st Annual Collaborative Care Conference, Novel Clinical Trials in Brain Tumors
2012	Speaker, Brain Tumors: 2 nd Annual Collaborative Care Conference Overview of Brain Cancers and Clinical Management
2012	Speaker, Brain Tumors: 2 nd Annual Collaborative Care Conference Overview of Brain Cancers
2012	Speaker, Brain Tumors: 2 nd Annual Collaborative Care Conference Novel Clinical Trials in Brain Cancers

Advisory and supervisory responsibilities:

2004-2009	Neurology clinic preceptor, ad hoc basis Brigham and Women's Hospital	10 hours/year
2004-2009	Neurology ward and consult services attending Brigham and Women's Hospital	80 hours/year
2004-2009	Teaching oncology fellows Center for Neuro-Oncology Clinic, Dana-Farber Cancer Institute	200 hours/year
2005-2009	Advising technicians, post-docs, and graduate students Department of Cancer Biology Dana-Farber Cancer Institute	400 hours/year
2006	Partners Neurology Career Planning Retreat Career Development in Basic Research in Neurology for residents	4 hours/year
2006-2007	Advising post-docs and technicians Functional and Molecular Imaging Center Brigham and Women's Hospital	200 hours/year
2009-present	Advising post-docs, student and technicians Translational Neuro-Oncology Laboratories UC San Diego, Moores Cancer Center	200 hours/year

Advisees/Trainees:*Clinical:*

2004-2005	Jan Drappatz	Neuro-Oncologist, UPMC
2005	Vassilios Markos	Oncologist, Greece
2005-2006	April Fitzsimmons	Neuro-Oncologist, MGH
2005-2006	Jeannie Grier	Neuro-Oncologist, Fallon Clinic
2005-2006	Milan Chheda	Neuro-Oncology Fellow, Partners
2005-2007	Andrew Norden	Neuro-Oncology Fellow, Partners
2005-2007	Andrew Chi	Neuro-Oncology Fellow, Partners
2006	Fetullah Gerin	Medical Student, Marmara University, Istanbul, Turkey
2006	Ozden Narin	Medical Student, Hacettepe University, Ankara, Turkey
2006	Denis Nastic	Medical Student, Umeå University,

2006	Maria Sundström	Umeå, Sweden Medical Student, Umeå University, Umeå, Sweden
2006-2008	Michelle Monje	Neurology Resident, Partners
2006-present	Jorg Dietrich	Neurology Resident, Partners
2007	Serra Akar	Medical Student, Hacettepe University, Ankara, Turkey
2007-2008	Jaime Imitola	Neurology Resident, Temple University
2007-2008	Angela Wabulya	Neurology Resident, Johns Hopkins
2008	Will Namwoo Cho	Undergraduate, Harvard University
2008	Michael Rasper	University of Munich, Germany Bayer Fellowship Program
2009	Ganesh Shankar	Medical Student, Harvard
2011	Christine Matthews	NP student clinical research preceptorship
2011	Veronica Bradley	UCSD Regents Scholar Research Initiative (RSRI) mentor program.
2012	Esther Wee	Pharmacy student preceptorship
2012	Tiffany Taylor	Biomedical Sciences Graduate Student
2012-2014	Matthew Wieduwilt, MD	NCLAM, National Council for Leadership in Academic Medicine early-career mentoring for junior faculty
2012-2014	David Piccioni, MD, PhD	Assistant Professor, UC San Diego
2014	Jennifer Sassman	Assistant Professor, UC San Diego Doctor of Nursing Practice Student, University of San Diego
<i>Research:</i>		
2006- 2007	Eva Fast	Ph.D. Graduate School, Boston University
2007- 2009	Chrissy Rooney	Research Technician, DFCI
2007-2009	Ryung S. Kim	Assistant Professor, Worcester Polytechnic Institute, MA
2008-2010	Jai Grewal	Neuro-Oncologist, NY
2008-2009	Stephan Ulmer	NeuroRadiologist, Germany
2008	Jong Woo Lee	Epilepsy Attending, Brigham and Women's Hospital
2008	Anastasia Krymkowski	Summer Fellow, NCI-Integrative Cancer Biology Program (ICBP)
2008-2010	Pankajavalli Ramakrishnan	Neurology Resident, Partners
2008-2010	Ning Lin	Neurosurgery Resident, BWH
2009	Laura K. Rosow	Medical Student, Harvard
2006-2009	Ana Borrás	Research Scientist, DFCI
2010-2013	Hubert Pan	Medical Student, UC San Diego
2010-2014	Ying Chao	Medical Student, SUNY
2011	Ali Mahta	Neurology Resident, Temple University

2012	Amy Rommel	Post-doc, Salk Institute
2013	Andreas Javier	Visiting fellow, UERMMMCI College of Medicine, Philippines
2013	Christine Som	Visiting Nurse Research (Phillipines)
2013	Jacqueline Bannach	Visiting Research Student (Germany)
2013	Heather Barnes	Undergrad, UCSD
2013	Kabir Chawla	Undergrad, UCSD
2013	Nikita Akkala	Undergrad, UCSD
2013	Navin Kesari	Medical Student, Rush University
2013-2014	Ali Shenasa	Undergrad, UCSD
2014-2014	Michael Qiu	Undergrad, UCSD
2014	Soumya Kurnool	Undergrad, UCSD
2014	Maria Ginzburg	Senior, High School
2014	Fatima Z. Housni	McNair Scholar, UCSD

Ph.D Thesis Advisor/Committee:

2009-2015	Marlon Saria	UCLA, School of Nursing
2010	Dayu Teng	UCSD, Department of Bioengineering
2011-2012	Navin R. Mahadevan	UCSD, School of Medicine
2010-present	Robert Saddawi-Konefka	UCSD, School of Medicine
2013-present	Jason Del Rio	UCSD, Biomedical Sciences

Post-Doctoral Advisor:

2009-2013	Sandra Pastorinio	University of Hawaii
2009-present	Pengfei Jiang	UC San Diego
2010-2013	Valentina Fogal	UC San Diego
2010-present	Milan Makale	UC San Diego
2010-present	Sandeep Pingle	UC San Diego
2014-present	Ivan Babic	UC San Diego
2013-present	Jeffrey Rodvold	UC San Diego

MPH Thesis Advisor/Committee:

2010-2011	Courtney Corle	San Diego State University, School of Public Health
2011-2012	Toni Rush	San Diego State University, School of Public Health
2012-2013	Katrina Flores	San Diego State University, School of Public Health
2013-2014	Jacob T. Rosalez	San Diego State University, School of Public Health
2014-2015	Natasia Courchesne	San Diego State University, School of Public Health

MA Thesis Advisor/Committee:

2010	Krithika Rao	Vellore Institute of Technology, India
2011	Bill Kemnitzer	MAS Clinical Research, UC San Diego
2012-2013	Rohit Saklecha	MS in Biology, UC San Diego
2014-2015	Manshi V. Mallepogu	MAS Clinical Research, UC San Diego

2. Regional, National, and International Contributions

Regional:

1996	Invited Speaker, Wistar Institute, Monica H. M. Shander Presentation, Studies of a Neuroattenuated Herpes Simplex Virus-1 in the Murine CNS, Philadelphia, Pennsylvania
1998	Invited Speaker, University of Pennsylvania School of Medicine Annual M.D.-Ph.D. Retreat, Herpes Simplex Virus for Treatment of CNS Tumors, Philadelphia, Pennsylvania
2001	Invited Speaker, Chief's Rounds, Boston Society of Neurology and Psychiatry, Mononeuritis Multiplex, Boston, Massachusetts
2001	Invited Speaker, 92 th Annual Meeting of Boston Society of Neurology and Psychiatry, Superficial Siderosis, Boston, Massachusetts
2004	Invited Speaker, Annual Brain Tumor Society Symposium, Late Effects of Treatment for Adults, Newton, Massachusetts
2006	Grand Rounds Speaker, Neurology-Neurosurgery Grand Rounds, Tufts-New England Medical Center, From Neural Stem Cells to Brain Tumors, Boston, Massachusetts
2007	Invited Speaker, Dana-Farber/Brigham and Women's Neuro-Oncology Conference, Translational platform for Neuro-Oncology, Boston, Massachusetts
2007	Invited Speaker, Adnexus, Inc. Gliomas 101: Brain tumors, stem cells, and therapeutics, Waltham, Massachusetts
2007	Invited Speaker, Dana-Farber/Brigham and Women's Neuro-Oncology Conference, Bench to Bedside and Back: Feedback Loops in Neuro-Oncology, Boston, Massachusetts
2008	Invited Speaker, Complex Biosystems Modeling Laboratory, Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Imaging of Human Tumor Stem Cells, Charlestown, Massachusetts
2008	Grand Rounds Speaker, Neurosurgery Grand Rounds, Brigham and Women's Hospital, Translational Studies in Brain Tumors, Boston, Massachusetts
2008	Invited Speaker, Worcester Polytechnic Institute, Optimizing Response Assessment Criteria for Brain Tumors, Worcester, Massachusetts
2008	Invited Speaker, Pain and Palliative Care Seminar, Dana-Farber Cancer Institute, Role of levetiracetam in chemotherapy-induced nausea/vomiting, Boston, Massachusetts
2008	Invited Speaker, Oncology and Stem Cell Seminar Series, Personalizing treatments for brain tumors through an integrated

- multimodal translational platform, Dana-Farber Cancer Institute, Boston, Massachusetts
- 2009 Invited Speaker, Center for Neurologic Diseases: Multiple Sclerosis Center, Neurological Complications of Novel Therapeutics: Case of Progressive Multifocal Leukoencephalopathy, Brigham and Women's Hospital, Boston, Massachusetts
- 2009 Invited Speaker, Brigham and Women's Hospital Neuro-Oncology Conference, Glioma Biomarker Project, Brigham and Women's Hospital, Boston, Massachusetts
- 2009 Invited Speaker, Neurosciences Retreat, Personalizing Treatments for Brain Tumors, University of California, San Diego, La Jolla, California
- 2009 Invited Speaker, Tumor Growth, Invasion, and Metastasis Program Annual Retreat, A Short Tour of Neuro-Oncology, University of California, San Diego, La Jolla, California
- 2009 Invited Speaker, Tumor Board, Progress in Neuro-Oncology and Opportunities to Improve Outcomes, Sharp Mary Birch Hospital for Women, San Diego, California
- 2009 Invited Speaker, Moores Cancer Center Research Meeting, Advances in Glioma Biology and Therapeutics, University of California, San Diego, San Diego, California
- 2009 Invited Speaker, Brain Tumor Board Special Seminar, Translational Neuro-Oncology: Opportunities to Improve Outcomes, University of California, Irvine, Irvine, California
- 2009 Invited Speaker, Moores Cancer Center Annual Scientific Faculty Retreat: Molecular basis of cancer therapy and prevention, University of California, San Diego, Genetics and targeted therapeutics in neuro-oncology, San Diego, California
- 2009 Invited Speaker, Seminar, Celgene, Targeted therapeutics in neuro-oncology, San Diego, California
- 2009 Grand Rounds Speaker, Department of Neurosciences, University of California, San Diego, Scientific and clinical advances in the management of brain tumors, San Diego, California
- 2009 Invited Speaker, Seminar, Translational Neuro-Oncology, Ludwig Institute for Cancer Research, San Diego, California
- 2009 Invited Speaker, Brain Tumor Board Seminar, Update on Glioma Treatments, City of Hope, Duarte, California
- 2010 Invited Speaker, Department of Hematology-Oncology, Naval Medical Center, San Diego, Translational Neuro-Oncology, San Diego, California
- 2010 Invited Speaker, Board of Directors Meeting, Neuro-Oncology Program Update, UCSD Moores Cancer Center, La Jolla, California
- 2010 Invited Speaker, Hematology/Oncology Section Meeting, Introduction to Neuro-Oncology, VA Medical Center, La Jolla, California
- 2010 Invited Speaker, Philippine Nursing Association, Bench to Bedside and Back: Implications to Personalized Medicine in Neuro-Oncology, Paradise Valley Hospital, San Diego, California

- 2010 Invited Speaker, San Diego Academy of Neurosurgery, Advancing Brain Tumor Treatments, San Diego, California
- 2010 Invited Speaker, Neuro-Oncology Conference, Overview of Neuro-Oncology, Moores UCSD Cancer Center, La Jolla, California
- 2010 Invited Speaker, Moores Infusion Center Conference, CNS Complication of Cancer, Moores UCSD Cancer Center, La Jolla, California
- 2010 Invited Speaker, Neuropathology Minisymposium, Accelerating Brain Cancer Treatments with Biomarker Discovery, UC San Diego, La Jolla, California
- 2011 Invited Speaker, Neurosurgery Grand Rounds, Accelerating Brain Cancer Treatments with Biomarker Discovery, UC San Diego, La Jolla, California
- 2011 Invited Speaker, Neuro-Oncology Family Information Day, Personalized brain cancer treatments across the age spectrum, Rady Children's Hospital, San Diego, California
- 2011 Invited Speaker, Neurology Grand Rounds, Accelerating Treatments for Brain Cancer, Cedars-Sinai Medical Center, Los Angeles, California
- 2011 Invited Speaker, NanoScience and Emerging Technology in Cancer Research. Encapsulation of Staurosporine Using a Novel Intraliposomal Stabilization Strategy: Therapeutic Efficacy in Glioma, UC San Diego, La Jolla, California
- 2012 Invited Speaker, Translational Neuro-oncology, Tocagen, San Diego, California
- 2012 Invited Speaker, Cancer Therapeutics Training Program (CT²) for oncology drug development, Targeting growth factor signaling in glioblastoma, University of California, San Diego, La Jolla, California
- 2012 Invited Speaker, Translational Neuro-Oncology, Tocagen, San Diego, California
- 2012 Invited Speaker, Update on Neuro-Oncology, San Diego Neurology Society, La Jolla, California
- 2012 Invited Grand Rounds Speaker, Advances in Neuro-Oncology: Opportunities to Improve Understanding of Tumor Biology, Department of Radiology, University of California, San Diego, La Jolla, California
- 2012 Invited Speaker, Neuro-Oncology Family Information Day, Personalized brain cancer treatments across the age spectrum, Rady Children's Hospital, San Diego, California
- 2012 Invited Speaker, Genomics Institute of the Novartis Research Foundation Seminar, Overview of Translational Neuro-Oncology: Opportunities for Novel Discovery and Drug Development, La Jolla, California
- 2012 Invited Speaker, Cancer Stem Cell Symposium, Brain Tumor Stem Cell Inhibition in Clinical Trials, Sanford Consortium for Regenerative Medicine, La Jolla, California

- 2013 Invited Speaker, Cancer Therapeutics Training Program (CT²) for oncology drug development, Development of New Drugs for Glioblastoma, University of California, San Diego, La Jolla, California
- 2013 Invited Speaker, NF Symposium, House Ear Institute/House Research Institute and NF California, Introduction to UCSD and Update on Optic Pathway Gliomas, Los Angeles, California
- 2013 Invited Speaker, Neuroscience Grand Rounds, Loma Linda University, Translational Neuro-Oncology: Opportunities to Improve Outcomes, Loma Linda, California
- 2013 Organizer and Speaker, NF Symposium in San Diego, Introduction to UC San Diego NF Program, La Jolla, California
- 2013 Invited Speaker, Solid Tumor Therapeutics Program, New and Innovative Clinical Trials in Neuro-Oncology, University of California, San Diego, La Jolla, California
- 2015 Invited Speaker, Neurosciences Grand Rounds, Translational Neuro-Oncology: Accelerating Discovery and Improving Outcomes, John Wayne Cancer Institute, Santa Monica, California
- 2015 *Invited Speaker, Neurology Grand Rounds, Translational Neurosciences: Opportunities to Improve Outcomes, University of California, Irvine, Irvine, California*

National:

- 2005 Invited Speaker, Schering-Plough Oncology North American Temodar Workshop, Interim Results of a Phase II Study of Prolonged Daily Temozolomide for Low-Grade Glioma, Atlanta, Georgia
- 2006 Invited Speaker, Accelerate Brain Cancer Cure Scientific Retreat, Beyond Angiogenesis Inhibitors – High-Throughput Phenotypic In Vitro/In Vivo Screens for the Identification of Small Molecule Modulators of Glioma Cell Migration and Invasion, Catalina, Arizona
- 2007 Invited Speaker, Sontag Foundation Annual Retreat, Role of Olig2 in Glioblastoma, St. Augustine, Florida
- 2007 Grand Rounds Speaker, Neurology Grand Rounds, Ohio State University Medical Center, Olig2 dependence in glioblastoma, Columbus, Ohio
- 2007 Grand Rounds Speaker, Neurology-Neurosurgery Grand Rounds, Mayo Clinic, An Olig2:p53 signaling axis for glioblastoma stem cells, Jacksonville, Florida
- 2007 Visiting Professor, Neurosurgery Grand Rounds, Washington University School of Medicine, Olig2:p53 signaling axis for glioblastoma stem cells, St. Louis, Missouri
- 2007 Grand Rounds Speaker, Neurology Grand Rounds, Northwestern University, Feinberg School of Medicine, Role of Olig2 in glioblastoma stem cells, Chicago, Illinois
- 2007 Grand Rounds Speaker, Clinical Neuroscience Grand Rounds, Yale University School of Medicine, Olig2:p53 axis for glioblastoma stem cells, New Haven, Connecticut

- 2007 Grand Rounds Speaker, Neurosurgery Grand Rounds, University of Utah, School of Medicine, Olig2 dependence in glioblastoma stem cells: Translational Studies in Neuro-Oncology, Salt Lake City, Utah
- 2008 Invited Speaker, Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Olig2 and Translational Studies in Neuro-Oncology, Miami, Florida
- 2008 Invited Speaker, Multimodality Management of Brain Tumors Conference, University of Texas, Memorial Hermann Hospital, Advances in Neuro-Oncology, Houston, Texas
- 2008 Keynote Speaker, Multimodality Management of Brain Tumors Conference, University of Texas, Memorial Hermann, Stem Cells and Brain Tumors: New Research Perspectives, Houston, Texas
- 2008 Visiting Professor, Neurological Sciences Grand Rounds, University of Nebraska Medical Center, Translational Studies in Gliomas, Omaha, Nebraska
- 2008 Invited Speaker, Sontag Foundation Annual Retreat, Olig2-P53 Signaling Axis in Glioblastoma, Jacksonville, Florida
- 2008 Invited Speaker, Oncological Sciences Seminar, Huntsman Cancer Institute, University of Utah, School of Medicine, Olig2 and Cell Cycle Regulation in Glioblastoma, Salt Lake City, Utah
- 2008 Grand Rounds Speaker, Neurology/ Neurosurgery Grand Rounds, University of Utah, Department of Neurology, Translational Studies in Neuro-Oncology, Salt Lake City, Utah
- 2008 Invited Speaker, Brain Tumor Center Seminar Series, Memorial Sloan Kettering Cancer Center, Olig2 and translational explorations in gliomas, New York, New York
- 2008 Invited Speaker, Oncology Seminar, Saint Michael's Medical Center, Therapy Considerations in Lymphomatous Meningitis, Newark, New Jersey
- 2008 Grand Rounds Speaker, Neuroscience Grand Rounds, Medical University of South Carolina, Recent Progress in Neuro-Oncology, Charleston, South Carolina
- 2008 Invited Speaker, Moores UCSD Cancer Center, University of California San Diego, Neuro-Oncology: At the Crossroads of Neuroscience, Cancer Biology and Development, San Diego, California
- 2009 Invited Speaker, Neuroscience Seminar Series, University of California San Diego, Translational Neuro-Oncology: Personalizing Treatments for Brain Tumors, San Diego, California
- 2009 Visiting Professor, Neurology Grand Rounds, University of Virginia, Stem Cells, Gliomagenesis, and Neoplastic Meningitis: Opportunities for Personalized Therapies, Charlottesville, Virginia
- 2009 Invited Speaker, Oncology Seminar, Lehigh Valley Hospital, Advances in the Management of Recurrent Glioblastoma, Allentown, Pennsylvania
- 2009 Invited Speaker, Sontag Foundation Annual Retreat, Update on Olig2 and Discovering Biomarkers of Treatment Response in Glioblastoma, Amelia Island, Florida

- 2009 Invited Speaker, Oncology Seminar, University of North Carolina, Scientific and Clinical Advances in Neuro-Oncology, Chapel Hill, North Carolina
- 2009 Invited Speaker, Neurology Grand Rounds, Vanderbilt University, Biological and Therapeutic Advances in Neuro-Oncology, Nashville, Tennessee
- 2009 Invited Speaker, The Science of BioBanking: Investing in the Future, Cambridge Healthtech Institute, Living Tissue Banks: The Road to Personalizing Treatments for Brain Tumors, Philadelphia, Pennsylvania
- 2009 Invited Speaker, Oncology Seminar, Neurological Surgery PC, Therapy Considerations in Lymphomatous Meningitis, Great Neck, New York
- 2009 Invited Speaker, Oncology Seminar, University of Louisville, Lymphomatous Meningitis and Advances in Glioma Therapies, Louisville, Kentucky
- 2009 Invited Speaker, Oncology Seminar, Community Cancer Care South, Therapy Considerations in Lymphomatous Meningitis, Indianapolis, Indiana
- 2010 Invited Speaker, NF1 Think Tank, Children's Tumor Foundation, Translating lessons from adult malignant brain tumors to neurofibromatosis research, New York, New York
- 2010 Co-facilitator, Workshop on *Genes and Oncology Research*, Public Responsibility in Medicine and Research (PRIM&R) Annual Meeting, San Diego, CA
- 2010 Grand Rounds Speaker, Department of Neurology, University of Oklahoma Health Sciences Center, Neuro-Oncology: Biomarker Discovery and Individualized Therapies, Oklahoma City, Oklahoma
- 2011 Invited Speaker, Biodesign Institute, Arizona State University, Clinical and Molecular Heterogeneity in Brain Cancers, Phoenix, Arizona
- 2011 Invited Speaker, Hematology and Medical Oncology Conference, Oregon Health and Science University, Progress in Neuro-Oncology, Portland, Oregon
- 2011 Invited Speaker, Neurosurgery Grand Rounds, University of Washington Medical Center, Improving Outcomes in Neuro-Oncology: Tumor Heterogeneity and Targeted Therapies, Seattle, Washington
- 2011 Invited Speaker, California Biologics Education Alliance, 2011 Biomedicine Roundtable, Safety of Biologics, La Jolla, CA
- 2012 Invited Speaker, Eradicating Brain Cancer, Yale University, Ongoing Trials using Small Molecule Inhibitors of Growth Promoting Pathways, New Haven, Connecticut
- 2012 Session Moderator, Eradicating Brain Cancer, Yale University, Current Therapies and Novel Agents in Clinical Trials, New Haven, Connecticut
- 2012 Invited Speaker, Cleveland Clinic Rose Ella Burkhardt Brain Tumor & Neuro-Oncology Center Rounds, Accelerating Discovery and

- Improving Outcomes in Neuro-Oncology: Tumor Heterogeneity and Targeted Therapies, Cleveland, Ohio
- 2012 Invited Speaker, Rhode Island Brain and Spine Foundation, Challenges in the Management of Glioblastoma, Providence, Rhode Island
- 2012 Invited Speaker, Neurology Grand Rounds, Brown University, Translational Neuro-Oncology: Opportunities to Improve Outcomes, Providence, Rhode Island
- 2012 Invited Speaker, Neurology Resident Teaching Conference, Brown University, Overview of Neuro-Oncology, Providence, Rhode Island
- 2012 Guest Speaker, Patient and Caregiver Conference/Awareness Day, New Treatment Options for Brain Cancer Patients, The Elliott Foundation, Seattle, WA
- 2012 Featured Speaker, Atlantic Meets the Pacific Conference, Panel on barriers facing the scientific community. Moderated by Steve Clemons, Washington editor at large of *The Atlantic*.
- 2012 Invited Speaker, Transforming tomorrow, today conference, National Brain Tumor Society 2012 Summit, Development of an *in silico* systems biology approach to personalizing GBM therapy, Boston, CA
- 2012 Invited Speaker, Brain Tumor Funders Collaborative, Multidisciplinary Research in Neuro-Oncology, BTFC workshop Changing the Future of Glioblastoma: Understanding the Pre and Post Treatment Milieu. The Physiology of Tumor Growth: How do alterations in the structural integrity of the tissue, the blood vessels, and the blood brain barrier contribute to the pre and post treatment environment? A Multi-Disciplinary Approach. St. Louis, Missouri
- 2012 Visiting Lecturer, Tisch Cancer Institute, Mount Sinai Medical Center, Translational Neuro-Oncology: Discovering Novel Targets and Approaches for Brain Cancers, New York, New York
- 2013 Invited Speaker, Cancer Biology Program, University of Hawaii Cancer Center, Translational Neuro-Oncology: Opportunities to Personalize Outcomes, Honolulu, Hawaii
- 2013 Invited Speaker, Translational Center of Excellence, Abramson Cancer Center, Perlman School of Medicine, University of Pennsylvania, [Advances in Brain Tumor Therapy](#), Philadelphia, Pennsylvania
- 2013 Invited Speaker, University of North Dakota, School of Medicine, Translational Neuroscience: Opportunities to Accelerate Discovery and Improve Outcomes, Fargo, North Dakota
- 2013 Invited Speaker, Neurosurgery Grand Rounds, Washington University School of Medicine, Translational Neuro-Oncology: Opportunities to Accelerate Discovery and Improve Outcomes, St. Louis, Missouri
- 2013 Invited Speaker, Molecular Profiling in the Clinical Management of Primary and Secondary Brain Tumors, Tucson, AZ
- 2013 Invited Speaker, Molecular Profiling in the Clinical Management of Primary and Secondary Brain Tumors, Phoenix, AZ
- 2013 Invited Speaker, Center for Cancer Research, National Institutes of Health, Translational Neuro-Oncology: Opportunities to Accelerate Discovery and Improve Outcomes, Bethesda, MD

- 2013 Keynote Speaker, 3rd Focus on Brain Cancer: Discovery to Recovery Conference, Abramson Cancer Center, Perlman School of Medicine, University of Pennsylvania, [Advances in Brain Tumor Therapy](#), Philadelphia, Pennsylvania
- 2013 Invited Speaker, ABTA Alumni Research Network (AARN) meeting, The Art of Persuasion – Convincing Others to Invest in You and Your Lab, Chicago, Illinois
- 2013 Invited Panelist, ABTA Alumni Research Network (AARN) meeting, Experiences with the NIH Scientific Review Processes, Chicago, Illinois
- 2013 Speaker, Sigma-Tau Pharmaceuticals, Enhanced Therapy and Treatment Options for Lymphomatous Meningitis, San Francisco, California
- 2013 Invited Speaker, First Annual Translational and Comparative Research Summit, Translational Neuro-Oncology: Opportunities to Accelerate Discovery and Improve Outcomes, Seattle, Washington
- 2014 Invited Speaker, Neurosurgery Conference, Oregon Health and Science University, Translational Neuro-Oncology: From Bench to Bedside and Back, Portland, Oregon
- 2014 Invited Speaker, 24th Annual Frontiers in Wyoming Medicine, Wyoming Medical Center, Recent Progress in [Brain Tumors](#), Casper, Wyoming
- 2014 Invited Speaker, 2nd Principal Investigators' Summit of Genelux Corporation, Memorial Sloan Kettering Cancer Center, Phase I/II Clinical Trials in Brain Cancers Using GL-ONC1, New York City, New York
- 2014 Invited Speaker, Neurology Grand Rounds, University of Texas at Austin, Translational Neuro-Oncology: Opportunities to Accelerate Discovery and Improve Outcomes, Austin, Texas
- 2014 Invited Speaker, Drug Resistance Evolution Meeting, Kavli Institute for Theoretical Physics, Personalizing therapies for brain cancers, Santa Barbara
- 2014 Grand Rounds Speaker, Neurology Grand Rounds, University of Texas at Houston, Translational Neuro-Oncology: Opportunities to Accelerate Discovery and Improve Outcomes, Houston, Texas
- 2014 Invited Speaker, Neurology Grand Rounds, University of Southern California, Translational Neurosciences: Accelerating Discoveries and Treatments in Brain Cancer, Los Angeles, California
- 2014 Invited Speaker, Angiochem ANG1005- CLN-04 Investigator Meeting, Management of Brain Metastases, Chicago, Illinois
- 2014 Invited Speaker, Partners in Care Conference, 16th Annual Brain Tumor Update and 5th Annual International Symposium on Long-Term Control of Metastases to the Brain and Spine, Primary Brain Tumor Treatment, Las Vegas, Nevada
- 2014 Invited Speaker, Using Molecular Targets to Guide Therapy: An Evidence-Guided Approach to Personalized Medicine, Las Vegas, Nevada

- 2014 Brain Tumor Study Group Speaker, Dardinger Center for Neuro Oncology, Ohio State University Medical Center, Developing New Approaches to Brain Cancers, Columbus, Ohio
- 2015 Special Seminar Speaker, Medical College of Wisconsin, Translational Neuro-Oncology: Opportunities to Accelerating Discovery and Improving Outcomes, Milwaukee, Wisconsin

International:

- 2003 Keynote Speaker, Founders Award, American Academy of Neurology, Prognostic Factors in Adult Brainstem Gliomas, Honolulu, Hawaii
- 2006 Grand Rounds Speaker, Ross University School of Medicine, Cancer Stem Cells and Brain Tumors, Portsmouth, Dominica
- 2006 Invited Speaker, Research Day Medical Symposium, Ross University School of Medicine, Neuro-Oncology: From Molecular Genetics to Targeted Treatments, Portsmouth, Dominica
- 2007 Invited Speaker, The Science of Prevention: New Insights into the Importance of Intra-CSF Prophylaxis, Stem Cells, the SVZ, and Gliomagenesis, St. Thomas
- 2007 Session Moderator, Chemotherapeutics II, The 2007 International Conference on Glioma Research and Therapy, Boston, MA
- 2007 Platform Speaker, Society for Neuro-Oncology, Phase II Study of Prolonged Daily Temozolomide for Low-Grade Glioma, Dallas, Texas
- 2008 Invited Speaker, Brain Tumor Research Center Grand Rounds, Hospital for Sick Kids, Role of Olig2 in human gliomagenesis, Toronto, Canada
- 2008 Invited Speaker, Neuroscience Grand Rounds, Toronto Western Hospital, Translational Studies in Neuro-Oncology, Toronto, Canada
- 2008 Invited Speaker, Clark H. Smith Brain Tumor Center Seminar, University of Calgary, Towards Personalized Treatment of Brain Tumors, Calgary, Canada
- 2009 Guest Faculty, Chongqing International Stroke and Neurological Forum, Neurological Society of Chinese Medical Association, Novel Treatment Approaches in Neuro-Oncology, Chongqing, China
- 2009 Visiting Professor, Jingzhou International Neurological Forum, Yangtze University, Progress in Neuro-Oncology, Jingzhou, China
- 2009 Visiting Professor, Guangdong International Neurological Forum, Guangdong 999 Brain Hospital, Jinan University, Translational Neuro-Oncology, Guangzhou, China
- 2009 Guest Faculty, Mumbai Neuro-Oncology Group, Emerging Management Strategies for Malignant Gliomas, Mumbai, India
- 2009 Visiting Professor, Tata Memorial Hospital, Current Status and Future Directions for Malignant Gliomas, Mumbai, India
- 2009 Guest Faculty, Inaugural Conference of the Neuro-Oncology Society of India, Conceptual and Clinical Progress in Neuro-Oncology, Delhi, India
- 2009 Guest Faculty, Inaugural Conference of the Neuro-Oncology Society of India, Chemotherapy in Low Grade Gliomas, Delhi, India

- 2009 Guest Faculty, Inaugural Conference of the Neuro-Oncology Society of India, How to do Translational Studies in Brain Tumors to Discover Biomarkers and Improve Survival, Delhi, India
- 2009 Keynote Speaker, 2009 Beijing International Neurological Forum, Military General Hospital of Beijing, Clinical and Scientific Progress in the Multidisciplinary Management of Brain Tumors, Beijing, China
- 2010 Guest Faculty, Annual Conference of the Indian Society of Neuro-Oncology, Biomarker Based Clinical Trials in Adult and Pediatric Neuro-Oncology, Chennai, India
- 2010 Guest Faculty, Annual Conference of the Indian Society of Neuro-Oncology, Update on Genomics and Signaling Aberrations from the Cancer Genome Atlas, Chennai, India
- 2011 Invited Speaker, Preuss Foundation Seminar on Glioma Biology: Recent Advances at the Edge of Discovery, Value of Human Xenografts, La Jolla, CA
- 2011 Guest Faculty, Annual Conference of the Indian Society of Neuro-Oncology, Where are we with targeted molecular therapy, Kolkata, India
- 2011 Keynote Speaker, 2011 Jinling Forum and Chinese Neuro-Oncology Conference, Standard of Care in Glioblastoma, Nanjing City, China
- 2011 Keynote Speaker, 2011 Chinese Society of Clinical Oncology Meeting, Chemotherapy in the Management of Malignant Gliomas, Xiamen, China
- 2012 Keynote Speaker, Advancements in Oncology-Navigate the New, Recent Advances in First Line Therapy in GBM and their Implications in Clinical Practice, Trivandrium, India
- 2012 Guest Faculty, 4th Annual Conference of the Indian Society of Neuro-Oncology, Response Biomarkers and Biomarker-Based Clinical Trials in Neuro-Oncology, Bangalore, India
- 2012 Invited Speaker, Medanta-The Medicity, Anti-angiogenic therapies for glioblastoma, New Delhi, India
- 2012 Invited Speaker, Neuro-Oncology Conference, Anti-angiogenic therapies for glioblastoma, Hyderabad, India
- 2012 Invited Speaker, Graduate School of Nursing, Chiba University, Brain Tumor Clinical Trial with Interdisciplinary Team Approach in UCSD Chiba, Japan
- 2012 Invited Speaker, The 3rd Global COE Symposium, Institute of Advanced Biomedical Engineering & Science, Graduate School of Medicine, Dept. of Neurosurgery, Neurological Institute, Tokyo Women's Medical University, Translational Neuro-Oncology: Accelerating Personalized Treatments for Brain Cancers, Tokyo, Japan
- 2012 Invited Speaker, Japanese Society for Neuro-Oncology, Tumor Treating Fields: A New Treatment Modality for Neuro-Oncology, Hiroshima, Japan
- 2012 Invited Speaker, Tata Memorial Hospital, New Devices in Neuro-Oncology, Mumbai, India
- 2012 Invited Speaker, Krishna Institute Medical Sciences, Advances in Neuro-Oncology, Hyderabad, India

- 2012 Invited Speaker, Omega Hospital, Advances in Neuro-Oncology, Hyderabad, India
- 2012 Invited Speaker, Apollo Hospitals, Advances in Neuro-Oncology and Opportunities for New Drugs and Devices, Hyderabad, India
- 2013 Invited Speaker, PDGFR Signaling and Resistance, Asian Society Neuro-Oncology/Indian Society Neuro-Oncology meeting, Mumbai, India
- 2014 Invited Speaker, Developing Novel Therapeutics for Brain Cancers, Etherapeutics, Oxford, UK
- 2014 Invited Speaker, Role of chemotherapy in low grade gliomas, Indian Society Neuro-Oncology meeting, Lucknow, India
- 2014 Invited Speaker, Anti-VEGF therapies in high grade gliomas, Indian Society Neuro-Oncology meeting, Lucknow, India
- 2014 Invited Speaker, Indian Medical Association, Update on Brain Cancer Therapies, Valentis Cancer Hospital, Meerut, India
- 2014 Invited Speaker, Indian Medical Association, Molecular Profiling and Personalized Cancer Treatments, Valentis Cancer Hospital, Meerut, India
- 2014 Invited Speaker, Development of novel small molecules that target glioblastoma stem cells, 20th International Conference on Brain Tumor Research and Therapy (ICBRT20), Lake Tahoe, California
- 2014 Invited Speaker, Department of Anatomical Pathology, Marmara University, Progress in Neuro-Oncology, Istanbul, Turkey
- 2014 Invited Speaker, Premeeting Course on Multidisciplinary management of high-grade glioma. Epidemiology and etiology of high-grade gliomas, 11th Meeting of the Asian Society Neuro-Oncology, Istanbul, Turkey
- 2014 Keynote Speaker, In silico development of glioblastoma stem cell inhibitor, 11th Meeting of the Asian Society Neuro-Oncology, Istanbul, Turkey
- 2014 Keynote Speaker, Deterministic in silico modeling predicts sensitivity of glioblastoma to targeted therapy, 11th Meeting of the Asian Society Neuro-Oncology, Istanbul, Turkey
- 2015 Platform Speaker, Updated Results of the Phase III Trial of TTFields in Newly-Diagnosed GBM, Indian Society Neuro-Oncology meeting, Kochi, India
- 2015 *Invited Speaker, Role of chemotherapy in low grade gliomas, 12th Meeting of the Asian Society Neuro-Oncology, Phillipines*

3. Description of major curriculum offerings, teaching cases or innovative educational programs developed

- 2001-2003 I conceived and implemented the idea of a shared neurology database (Neuro1) for the Partners Neurology Residency program. This along with other technologies have supported the development of a growing knowledge base, which includes digitally stored and archived journal articles, clinical neuroimaging data, videos of patients and conferences, patient databases, images from weekly neuropathology

conferences, and resident handbooks. Even after my departure from residency, this database continues to be used daily by our Neurology residents and staff in diverse ways for teaching and clinical care purposes. This site has now been transformed into a wiki site by successive generations of residents.

E. Report of Clinical Activities

I am the Director of Neuro-Oncology at Moores UC San Deigo Moores Cancer Center and Chief of Division of Neuro-Oncology in the Department of Neurosciences at UCSD that includes administration and supervision of all personnel (physicians, fellows, nurses, nurse practioneers, clinical research coordinators, support staff) involved in the care of inpatients and outpatients seen by the neuro-oncology service.

I see patients in the Neuro-Oncology Clinic at Moores Cancer Center and in the Department of Neurology Outpatient Clinic at the Thornton Hospital. I care for approximately 300 patients with complex neurological, neuro-oncological, and neurosurgical problems in the outpatient clinic, and when admitted to the hospital. I also attend on the Neurology Inpatient and Consult Service at the Thornton Hospital for 2-4 weeks per year, during which time approximately 80-120 new patients are assessed. I teach oncology clinical fellows, neurology residents, nurses, nurse practioners and medical students during my clinical services.

I organize and direct the weekly multidisciplinary Brain Tumor Board devoted to clinical management of patients. Additionally, I also organize a weekly didactic neuro-oncology conference where we have both basic science and clinical talk on various topics relevant to neuro-oncology with speakers within and outside of UC San Diego.

PART III: Bibliography

Original Articles: *Senior/corresponding author

1. Randazzo BP, **Kesari S**, Gesser RM, Alsop D, Ford JC, Brown SM, MacLean AR, Fraser NW. Treatment of experimental intracranial murine melanoma with a neuroattenuated herpes simplex virus 1 mutant. *Virology* 1995;211(1):94-101. PMID: 7645240
2. **Kesari S**, Randazzo BP, Nagy T, Huang QS, Brown SM, MacLean AR, Lee VM, Trojanowski JQ, Fraser NW. Therapy of experimental human brain tumors using a neuroattenuated herpes simplex virus mutant. *Laboratory Investigation* 1995;73(5):636-48. PMID: 7474937
3. **Kesari S**, Lee VM, Brown SM, Trojanowski JQ, Fraser NW. Selective vulnerability of mouse CNS neurons to latent infection with a neuroattenuated herpes simplex virus-1. *Journal of Neuroscience* 1996;16(18):5644-53. PMID: 8795620
4. Lasner TM, **Kesari S**, Brown SM, Lee VM, Fraser NW, Trojanowski JQ. Therapy of a murine model of pediatric brain tumors using a herpes simplex virus type-1 ICP34.5 mutant and demonstration of viral replication within the CNS. *Journal of Neuropathology and Experimental Neurology* 1996;55(12):1259-69. PMID: 8957450
5. Wolfe JH, Martin CE, Deshmane SL, Reilly JJ, **Kesari S**, Fraser NW. Increased susceptibility to the pathogenic effects of wild-type and recombinant herpesviruses in MPS VII mice compared to normal siblings. *Journal of Neurovirology* 1996;2(6):417-22. PMID: 8972424
6. Randazzo BP, Bhat MG, **Kesari S**, Fraser NW, Brown SM. Treatment of experimental subcutaneous human melanoma with a replication-restricted herpes simplex virus mutant. *Journal of Investigative Dermatology* 1997;108(6):933-7. PMID: 9182825
7. Huang QS, Nagy T, **Kesari S**, Fraser NW. Beta-gal enzyme activity driven by the HSV LAT promoter does not correspond to Beta-gal RNA levels in mouse trigeminal ganglia. *Gene Therapy* 1997;4(8):797-807. PMID: 9338008
8. Randazzo BP, Tal-Singer R, Zabolotny JM, **Kesari S**, Fraser NW. Herpes simplex virus 1716, an ICP 34.5 null mutant, is unable to replicate in CV-1 cells due to a translational block that can be overcome by coinfection with SV40. *Journal of General Virology* 1997;78(12):3333-9. PMID: 9400985
9. **Kesari S**, Lasner TM, Balsara KR, Randazzo BP, Lee VM, Trojanowski JQ, Fraser NW. A neuroattenuated ICP34.5-deficient herpes simplex virus type 1 replicates in ependymal cells of the murine central nervous system. *Journal of General Virology* 1998;79(3):525-36. PMID: 9519831
10. Lasner TM, Tal-Singer R, **Kesari S**, Lee VM, Trojanowski JQ, Fraser NW. Toxicity and neuronal infection of a HSV-1 ICP34.5 mutant in nude mice. *Journal of Neurovirology* 1998;3(1):100-5. PMID: 9531017

11. Springer SL, Vite CH, Polesky AC, **Kesari S**, Fraser NW, Wolfe JH. Infection and establishment of latency in the dog brain after direct inoculation of a nonpathogenic strain of herpes simplex virus-1. *Journal of Neurovirology* 2001;7(2):149-54. PMID: 11517387

12. Shah GD*, **Kesari S***, Xu R, Batchelor TT, O'Neill AM, Hochberg FH, Levy B, Bradshaw J, Wen PY. Comparison of linear and volumetric criteria in assessing tumor response in adult high-grade gliomas. *Neuro-Oncology* 2006;8(1):38-46. PMID: 16443946

***Co-First Authors**

13. Ligon KL, **Kesari S**, Kitada M, Sun T, Arnett HA, Alberta JA, Anderson DJ, Stiles CD, Rowitch DH. Development of NG2 neural progenitor cells requires Olig gene function. *Proceedings of the National Academy of Sciences* 2006;103(20):7853-8. PMID: 16682644

14. Wüthrich C, **Kesari S**, Kim WK, Williams K, Gelman R, Elmeric D, De Girolami U, Joseph JT, Hedley-Whyte T, Korolnik IJ. Characterization of lymphocytic infiltrates in progressive multifocal leukoencephalopathy: Co-localization of CD8(+) T cells with JCV-infected glial cells. *Journal of Neurovirology* 2006;12(2):116-28. PMID: 16798673

15. Doherty L, Gigas DC, **Kesari S**, Drappatz J, Kim R, Zimmerman J, Ostrowsky L, Wen PY. Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas. *Neurology* 2006;67(1):156-8. PMID: 16832099

16. Jackman DM, Holmes AJ, Lindeman N, Wen PY, **Kesari S**, Borrás AM, Bailey C, de Jong F, Jänne PA, Johnson BE. Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. *Journal of Clinical Oncology* 2006;24(27):4517-20. PMID: 16983123

17. Khwaja FW, Reed MS, Olson JJ, Schmotzer BJ, Gillespie GY, Guha A, Groves MD, **Kesari S**, Pohl J, Van Meir EG. Proteomic identification of biomarkers in the cerebrospinal fluid (CSF) of astrocytoma patients. *Journal of Proteome Research* 2007;6(2):559-70. PMID: 17269713

18. Ligon KL, Huillard E, Mehta S, **Kesari S**, Liu H, Alberta JA, Bachoo RM, Kane M, Louis DN, DePinho RA, Anderson DJ, Stiles CD, Rowitch DH. Olig2-regulated lineage-restricted pathway controls replication competence in neural stem cells and malignant glioma. *Neuron* 2007;53(4):503-17. PMID: 17296553

19. **Kesari S**, Schiff D, Doherty L, Gigas DC, Batchelor TT, Muzikansky A, O'Neill A, Drappatz J, Chen-Plotkin AS, Ramakrishna N, Weiss SE, Levy B, Bradshaw J, Kracher J, Laforme A, Black PM, Folkman J, Kieran M, Wen PY. Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults. *Neuro-Oncology* 2007;9(3): 354-63. PMID: 17452651

20. Evans CL, Xu X, **Kesari S**, Xie XS, Wong ST, Young GS. Chemically-selective imaging of brain structures with CARS microscopy. *Optics Express* 2007;15(19):12076-87. PMID: 19547572

21. Norden AD, Young GS, Setayesh K, Muzikansky A, Kulfas R, Ross GL, Ciampa AS, Ebbeling LG, Levy B, Drappatz J, **Kesari S**, Wen PY. Bevacizumab for recurrent malignant

gliomas: Efficacy, toxicity, and patterns of recurrence. *Neurology* 2008;70(10):779-87. PMID: 18316689

22. **Kesari S***, Kim RS, Markos V, Drappatz J, Wen PY, Pruitt AA. Prognostic factors in adult brainstem gliomas: A multicenter, retrospective analysis of 101 cases. *Journal of Neuro-Oncology* 2008;88(2):175-83. PMID: 18365144

***Senior/corresponding author**

23. **Kesari S**, Schiff D, Henson JW, Muzikansky A, Gigas DC, Doherty L, Batchelor TT, Longtine JA, Ligon KL, Weaver S, Laforme A, Ramakrishna N, Black PM, Drappatz J, Ciampa A, Folkman J, Kieran M, Wen PY. Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults. *Neuro-Oncology* 2008;10(3):300-8. PMID: 18403492

24. Drappatz J, Wong ET, Schiff D, **Kesari S**, Batchelor TT, Doherty L, LaFrankie DC, Ramakrishna N, Weiss S, Smith ST, Ciampa A, Zimmerman J, Ostrowsky L, David K, Norden A, Barron L, Sceppa C, Black PM, Wen PY. A pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiforme. *International Journal of Radiation Oncology Biology Physics* 2009;73(1):222-7. Epub 2008 May 29. PMID: 18513880

25. Lee JW, Bromfield EB, **Kesari S***. Emesis responsive to levetiracetam. *Journal of Neurology, Neurosurgery, and Psychiatry* 2008;79(7):847-9. PMID: 18559467

***Senior/corresponding author**

26. Gabriely G, Wurdinger T, **Kesari S**, Esau CC, Burchard J, Linsley PS, Krichevsky AM. MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators. *Molecular and Cellular Biology* 2008;28(17):5369-80. PMID: 18591254

27. Musunuru K, **Kesari S***. Paraneoplastic opsoclonus-myoclonus ataxia associated with non-small-cell lung carcinoma. *Journal of Neuro-Oncology* 2008; 90(2):213-6. PMID: 18618225

***Senior/corresponding author**

28. **Kesari S***, Akar S, Saad A, Drappatz J, Koralnik I, DeAngelo DJ. Progressive multifocal leukoencephalopathy in a patient with relapsed acute myelogenous leukemia. *Journal of Clinical Oncology* 2008;26(22):3804-7. PMID: 18669471

***Senior/corresponding author**

29. Stegh AH, **Kesari S**, Mahoney JE, Jenq HT, Forloney KL, Protopopov A, Louis DN, Chin L, DePinho RA. Bcl2L12-mediated inhibition of effector caspase-3 and caspase-7 via distinct mechanisms in glioblastoma. *Proceedings of the National Academy of Sciences* 2008;105(31):10703-8. PMID: 18669646

30. Ziegler DS, Wright RD, **Kesari S**, Lemieux ME, Tran MA, Jain M, Zawel L, Kung AL. Resistance of human glioblastoma multiforme cells to growth factor inhibitors is overcome by blockade of inhibitor of apoptosis proteins. *Journal of Clinical Investigation* 2008;118(9):3109-22. PMID: 18677408

31. Sauvageot CM, Weatherbee JL, **Kesari S**, Winters SE, Barnes J, Dellagatta J, Ramakrishna NR, Stiles CD, Kung AL, Kieran MW, Wen PY. Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells. *Neuro-Oncology* 2009;11(2):109-21. PMID: 18682579
32. Norden AD, Drappatz J, Ciampa AS, Doherty L, LaFrankie DC, **Kesari S**, Wen PY. Colon perforation during anti-angiogenic therapy for malignant glioma. *Neuro-Oncology* 2009;11(1):92-5. PMID: 18757774
33. Bracht LK, Wen P, Meyerhardt JA, Kulke MH, Hornick JL, Redston M, LaFrankie DC, Black PM, **Kesari S**, Norden A, Drappatz J. DNA repair enzyme expression and differential response to temozolomide in a patient with both glioblastoma and metastatic pancreatic neuroendocrine tumor. *Journal of Clinical Oncology* 2008;26(29):4843-4. PMID: 18779600
34. Ulmer S, Liess C, **Kesari S**, Otto N, Straube T, Jansen O. Use of dynamic susceptibility-contrast MRI (DSC-MRI) to assess perfusion changes in the ipsilateral brain parenchyma from glioblastoma. *Journal of Neuro-Oncology* 2009;91(2):213-20. Epub 2008 Sep 21. PMID: 18807224
35. Lee JW, Bromfield EB, **Kesari S***. Antiemetic properties of the antiepileptic drug levetiracetam. *New England Journal of Medicine* 2008;359(17):1853. PMID: 18946077
***Senior/corresponding author**
36. Norden AD, Drappatz J, Muzikansky A, David K, Gerard M, McNamara MB, Phan P, Ross A, **Kesari S**, Wen PY. An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma. *Journal of Neuro-Oncology* 2009;92(2):149-55. PMID: 19043778
37. Wüthrich C, Cheng YM, Joseph JT, **Kesari S**, Beckwith C, Stopa E, Bell JE, Korolnik IJ. Frequent infection of cerebellar granule cell neurons by polyomavirus JC in progressive multifocal leukoencephalopathy. *Journal of Neuropathology and Experimental Neurology* 2009;68(1):15-25. PMID: 19104450
38. Kolesnikova TV, Kazarov AR, Lemieux ME, Lafleur MA, **Kesari S**, Kung AL, Hemler ME. Glioblastoma inhibition by cell surface immunoglobulin protein EWI-2, in vitro and in vivo. *Neoplasia* 2009;11(1):77-86. PMID: 19107234
39. Ng K, Nitta M, Hu L, **Kesari S**, Kung A, D'Andrea A, Chen CC. A small interference RNA screen revealed proteasome inhibition as strategy for glioblastoma therapy. *Clinical Neurosurgery* 2009;56:107-18. PMID: 20214041
40. **Kesari S**, Schiff D, Drappatz J, LaFrankie D, Doherty L, Macklin EA, Muzikansky A, Santagata S, Ligon KL, Norden AD, Ciampa A, Bradshaw J, Levy B, Radakovic G, Ramakrishna N, Black PM, Wen PY. Phase II study of protracted daily temozolomide for low-grade gliomas in adults. *Clinical Cancer Research* 2009;15(1):330-7. PMID: 19118062
41. Wen PY, Yung WK, Lamborn KR, Norden AD, Cloughesy TF, Abrey LE, Fine HA, Chang SM, Robins HI, Fink K, DeAngelis LM, Mehta M, Di Tomaso E, Drappatz J, **Kesari S**, Ligon KL, Aldape K, Jain RK, Stiles CD, Egorin MJ, Prados MD. Phase II study of imatinib mesylate

for recurrent meningiomas (North American Brain Tumor Consortium Study 01-08). *Neuro-Oncology* 2009;11(6):853-60. PMID: 19293394

42. Quant EC, Norden AD, Drappatz J, Muzikansky A, Doherty L, LaFrankie D, Ciampa A, **Kesari S**, Wen PY. Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab. *Neuro-Oncology* 2009;11(5):550-5. PMID: 19332770

43. Wakimoto H, **Kesari S**, Farrell CJ, Curry WT Jr, Zaupa C, Aghi M, Kuroda T, Stemmer-Rachamimov A, Shah K, Liu TC, Jeyaretna DS, Debasitis J, Pruszk J, Martuza RL, Rabkin SD. Human glioblastoma-derived cancer stem cells: Establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. *Cancer Research* 2009;69(8):3472-81. PMID: 19351838

44. Zhao H, Zhu J, Cui K, Xu X, O'Brien M, Wong KK, **Kesari S**, Xia W, Wong ST. Bioluminescence imaging reveals inhibition of tumor cell proliferation by Alzheimer's amyloid beta protein. *Cancer Cell International* 2009;9:15. PMID: 19480719

45. Richardson PG, Xie W, Mitsiades C, Chanan-Khan AA, Lonial S, Hassoun H, Avigan DE, Oaklander AL, Kuter DJ, Wen PY, **Kesari S**, Briemberg HR, Schlossman RL, Munshi NC, Heffner LT, Doss D, Esseltine D, Weller E, Anderson KC, Amato AA. Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlates with response and neuropathy. *Journal of Clinical Oncology* 2009;27(21):3518-25. PMID: 19528374

46. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving Hh, Remuzzi G, Singh AK, Solomon SD, Toto R, TREAT Investigators (**Kesari S**). A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. *New England Journal of Medicine* 2009;361(21):2019-32. PMID: 19880844

47. Marzocchetti A, Tompkins T, Clifford DB, Gandhi RT, **Kesari S**, Berger JR, Simpson DM, Proserpi M, De Luca A, Koralnik IJ. Determinants of survival in progressive multifocal leukoencephalopathy. *Neurology* 2009;73(19):1551-8. PMID: 19901246

48. Grewal J, Zhou H, Factor R, **Kesari S***. Isolated loss of hormonal receptors in leptomeningeal metastasis from estrogen receptor- and progesterone receptor-positive lobular breast cancer. *Journal of Clinical Oncology* 2010;28(13):e200-2. PMID: 20124173

***Senior/corresponding author**

49. Drappatz J, Norden AD, Wong ET, Doherty LM, LaFrankie DC, Ciampa A, **Kesari S**, Sceppa C, Gerard M, Phan P, Schiff D, Batchelor TT, Ligon KL, Young G, Muzikansky A, Weiss SE, Wen PY. Phase I study of vandetanib with radiotherapy and temozolomide for newly-diagnosed glioblastoma. *International Journal of Radiation Oncology Biology Physics* 2010;78(1):85-90. PMID: 20137866

50. Zeng Q, Yang Z, Gao Y, Yuan H, Cui K, Shi Y, Wang Y, Huang X, Wong ST, Wang Y, **Kesari S**, Ji RR, Xu X. Treating triple-negative breast cancer by a combination of rapamycin and

cyclophosphamide: an in vivo bioluminescence imaging study. *European Journal of Cancer* 2010;46(6):1132-43. PMID: 20156674

51. Lee JW, Wen PY, Hurwitz S, Black P, **Kesari S**, Drappatz J, Golby AJ, Wells WM 3rd, Warfield SK, Kikinis R, Bromfield EB. Morphological characteristics of brain tumors causing seizures. *Archives of Neurology* 2010;67(3):336-42. PMID: 20212231

52. Nitta M, Kozono D, Kennedy R, Stommel J, Ng K, Zinn PO, Kushwaha D, **Kesari S**, Inda MD, Wykosky J, Furnari F, Hoadley KA, Chin L, DePinho RA, Cavenee WK, D'Andrea A, Chen CC. Targeting EGFR induced oxidative stress by PARP1 inhibition in glioblastoma therapy. *PLoS One* 2010;5(5):e10767. PMID: 20532243

53. Nghiemphu PL, Wen PY, Lamborn KR, Drappatz J, Robins HI, Fink K, Malkin MG, Lieberman FS, DeAngelis LM, Torres-Trejo A, Chang SM, Abrey L, Fine HA, Demopoulos A, Lassman AB, **Kesari S**, Mehta MP, Prados MD, Cloughesy TF; North American Brain Tumor Consortium. A phase I study of tipifarnib with radiation therapy, with and without temozolomide, for patients with newly diagnosed glioblastoma. *International Journal of Radiation Oncology Biology Physics* 2011;81(5):1422-7. PMID: 20934264

54. Chen J*, **Kesari S***, Rooney C, Strack PR, Chen J, Shen H, Wu L, Griffin JD. Inhibition of notch signaling blocks growth of glioblastoma cell lines and tumor neurospheres. *Genes and Cancer* 2010;1(8):822-35. PMID: 21127729

***Co-First Authors**

55. Young GS, Macklin EA, Setayesh K, Lawson JD, Wen PY, Norden AD, Drappatz J, **Kesari S***. Longitudinal MRI evidence for decreased survival among periventricular glioblastomas. *J Neuro-Oncology* 2011;104(1):261-9. PMID: 21132516

***Senior/corresponding author**

56. Erten A, Hall D, Hoh C, Tran Cao HS, Kaushal S, Esener S, Hoffman RM, Bouvet M, Chen J, **Kesari S**, Makale M. Enhancing magnetic resonance imaging tumor detection with fluorescence intensity and lifetime imaging. *J Biomed Opt* 2010;15(6):066012. PMID: 21198186

57. Wong K, Young GS, Makale M, Hu X, Yildirim N, Cui K, Wong ST, **Kesari S***. Characterization of a human tumorsphere glioma orthotopic model using magnetic resonance imaging. *J Neuro-Oncology* 2011;104(2):473-81. PMID: 21240539

***Senior/corresponding author**

58. Chaponis D, Barnes JW, Dellagatta JL, **Kesari S**, Fast E, Sauvageot C, Panagrahy D, Greene ER, Ramakrishna N, Wen PY, Kung AL, Stiles C, Kieran MW. Lonafarnib (SCH66336) improves the activity of temozolomide and radiation for orthotopic malignant gliomas. *J Neuro-Oncology* 2011;104(1):179-89. PMID: 21246394

59. Soda Y, Marumoto T, Friedmann-Morvinski D, Soda M, Liu F, Michiue H, Pastorino S, Yang M, Hoffman RM, **Kesari S**, Verma IM. Transdifferentiation of glioblastoma cells into vascular endothelial cells. *Proc Natl Acad Sci* 2011;108(11):4274-80. PMID: 21262804

60. Mehta S, Huillard E, **Kesari S**, Maire CL, Golebiowski D, Harrington EP, Alberta JA, Kane MF, Theisen M, Ligon KL, Rowitch DH, Stiles CD. The Central Nervous System-Restricted Transcription Factor Olig2 Opposes p53 Responses to Genotoxic Damage in Neural Progenitors and Malignant Glioma. *Cancer Cell* 2011;19(3):359-71. PMID: 21397859
61. Agnihotri S, Wolf A, Munoz DM, Smith CJ, Gajadhar A, Restrepo A, Clarke ID, Fuller GN, **Kesari S**, Dirks PB, McGlade CJ, Stanford WL, Aldape K, Mischel PS, Hawkins C, Guha A. A GATA4-Regulated Tumor Suppressor Network Represses Formation of Malignant Human Astrocytoma. *J Exp Medicine* 2011;208(4):689-702. PMID: 21464220
62. Gabriely G, Yi, M, Narayan RS, Niers JM, Wurdinger T, Imitola J, Ligon KL, **Kesari S**, Esau C, Stephens RM, Tannous BA, Krichevsky AM. Human glioma growth is controlled by microRNA-10b. *Cancer Research* 2011;71(10):3563-72. PMID: 21471404
63. Gheuens S, Bord E, **Kesari S**, Simpson DM, Gandhi RT, Clifford DB, Berger JR, Ngo L, Koralknik IJ. Role of CD4+ and CD8+ T-Cell responses against JC virus in the outcome of patients with progressive multifocal leukoencephalopathy (PML) and PML with immune reconstitution inflammatory syndrome. *J Virology* 2011;85(14):7256-63. PMID: 21543472
64. Larman HB, Zhao J, Laserson U, Li MZ, Ciccia A, Gakidis MA, Church GM, **Kesari S**, LeProust EM, Solimini NL, Elledge SJ. Autoantigen discovery with a synthetic human peptidome. *Nature Biotechnology* 2011;29(6):535-41. PMID: 21602805
65. Yu-Chang L, **Kesari S**, Bing L, Ya-Suo D, Ming-Zhi P. Individual management of recurrent intracranial aneurysms: The Wuxi Experience. *Cell Biochem Biophys* 2011;61(2):349-54. PMID: 21706366
66. Lin N, Dunn IF, Glantz M, Allison DL, Jensen R, Johnson MD, Friedlander RM, **Kesari S***. Benefit of ventriculoperitoneal cerebrospinal fluid shunting and intrathecal chemotherapy in neoplastic meningitis: a retrospective, case-controlled study. *J Neurosurgery* 2011;115(4):730-6. PMID: 21721878
- *Senior/corresponding author**
67. Ziegler DS, Keating J, **Kesari S**, Fast EM, Zawel L, Ramakrishna N, Barnes J, Kiernan MW, Veldhuijzen van Zanten SE, Kung AL. A small molecule IAP inhibitor overcomes resistance to cytotoxic therapies in malignant gliomas in vitro and in vivo. *Neuro-Oncology* 2011;13(8):820-9. PMID: 21724651
68. Mukthavaram R, Wrasidlo W, Hall D, **Kesari S***, Makale M. Assembly and targeting of liposomal nanoparticles encapsulating quantum dots. *Bioconjugate Chemistry* 2011;22(8):1638-44. PMID: 21786821
- *Co-Senior/corresponding author**
69. Cho J, Pastorino S, Zeng Q, Xu X, Johnson W, Vandenberg S, Verhaak R, Cherniack A, Watanabe H, Dutt A, Chao YS, Onofrio RC, Rooney C, Chiang D, Yuza Y, **Kesari S***, Meyerson M. Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies. *Cancer Research* 2011 Dec 15;71(24):7587-96. Epub 2011 Oct 14. PMID: 22001862

***Co-Senior/corresponding author**

70. Santagata S, Xu YM, Wijeratne EM, Kontnik R, Rooney C, Perley CC, Kwon H, Clardy J, **Kesari S**, Whitesell L, Lindquist S, Gunatilaka AA. Using the Heat-Shock Response to Discover Anticancer Compounds that Target Protein Homeostasis. *ACS Chemical Biology* 2012;7(2):340-9. PMID: 22050377

71. Pan H, Alksne J, Mundt AJ, Murphy KT, Cornell M, **Kesari S***, Lawson JD. Patterns of Imaging Failures in Glioblastoma Patients Treated with Chemoradiation: A Retrospective Study. *Medical Oncology* 2012;29(3):2040-5. PMID: 22108847

***Co-Senior/corresponding author**

72. Erten A, Makale M, Lu X, Serra V, Fruhberger B, **Kesari S**, Esener S. Streamlined cryogenic deep reactive ion etching protocol for hybrid micronozzle arrays. *J. Micromech. Microeng* 2011;21(10):105001. *PMID:*

73. Fu H, **Kesari S**, Cai J. Tcf712 is Tightly Controlled During Myelin Formation. *Cell Mol Neurobiol* 2012;32(3):345-52. PMID: 22160878

74. Ulmer S, Spalek K, Nabavi A, Schultka S, Mehdorn HM, **Kesari S**, Dorner L. Temporal changes in magnetic resonance imaging characteristics of Gliadel wafers and of the adjacent brain parenchyma. *Neuro-Oncology* 2012;14(4):482-90. PMID: 22319220

75. Teplyuk NM, Mollenhauer B, Gabriely G, Giese A, Kim E, Smolsky M, Kim RY, Saria MG, Pastorino S, **Kesari S***, Krichevsky AM. MicroRNAs in cerebrospinal fluid identify glioblastoma and metastatic brain cancers and reflect disease activity. *Neuro-Oncology* 2012;14(6):689-700. PMID: 22492962

***Co-Senior/corresponding author**

76. Chao Y, Makale M, Karmali PP, Sharikov Y, Tsigelny IF, Merkulov S, **Kesari S**, Wrasdilo W, Ruoslahti E, Simberg D. Recognition of dextran-superparamagnetic iron oxide nanoparticle conjugates (Feridex) via macrophage scavenger receptor charged domains. *Bioconjug Chem* 2012;23(5):1003-9. PMID: 22515422

77. Krop I, Demuth T, Guthrie T, Wen PY, Mason WP, Chinnaiyan P, Butowski N, Groves MD, **Kesari S**, Freedman SJ, Blackman S, Watters J, Loboda A, Podtelezchnikov A, Lunceford J, Chen C, Giannotti M, Hing J, Beckman R, LoRusso P. Phase I Pharmacologic and Pharmacodynamic Study of the Gamma Secretase (Notch) inhibitor MK-0752 in Adult Patients with Advanced Solid Tumors. *J Clin Oncol* 2012;30(19):2307-13. PMID: 22547604

78. Elbabaa SK, Gokden M, Crawford JR, **Kesari S**, Saad AG. Radiation-Associated Meningiomas in Children: Clinical, Pathological and Cytogenetic Characteristics with a Critical Review of the Literature. *J Neurosurgery Pediatrics* 2012;10(4):281-90. PMID: 22900483

79. Freudiger CW, Pfannl R, Orringer DA, Saar BG, Ji M, Zeng Q, Ottoboni L, Ying W, Waeber C, Sims JR, DeJager PL, Sagher O, Philbert MA, Xu X, **Kesari S**, Xie XS, Young GS. Multicolored Stain-free Histopathology with Coherent Raman Imaging. *Laboratory Investigation* 2012;92(11):1492-502. PMID: 22906986

80. White NS, McDonald CR, Farid N, Kuperman J, **Kesari S***, Dale AM*. Improved conspicuity and delineation of high-grade primary and metastatic brain tumors using “restriction spectrum imaging”: Quantitative comparison with high b-value DWI and ADC. *AJNR* 2013;34(5):958-64. PMID: 23139079

***Co-Senior/corresponding author**

81. MacDonald CR, White NS, Farid N, Bartsch H, Lai G, Hagler DJ, **Kesari S**, Carter BS, Chen CC, Dale AM. Recovery of White Matter Tracts in Regions of Peritumoral Edema Using Restriction Spectrum Imaging. *AJNR* 2013;34(6):1157-63. PMID: 23275591

82. Yost SE, Pastorino S, Rozenzhak S, Smith EN, Chao YS, Jiang P, **Kesari S***, Frazer K, Harismandy O. High-resolution mutational profiling suggests the genetic validity of glioblastoma patient-derived pre-clinical models. *PLoS One* 2013;8(2):e56185. PMID: 23441165

***Co-Senior/corresponding author**

83. Saria MG, Corle C, Hu J, Rudnick J, Phuphanich S, Mrugala MM, Crew LK, Bota DA, Dan Fu B, Kim RY, Brown T, Feely H, Brechlin J, Brown BD, Drappatz J, Wen PY, Chen CC, Carter B, Lee JW, **Kesari S***. Retrospective analysis of the tolerability and activity of lacosamide in patients with brain tumors. *J. Neurosurgery* 2013;118(6):1183-7. PMID: 23451905

***Senior/corresponding author**

84. Zhu J, Larman HB, Gao G, Somwar R, Zhang Z, Laserson U, Ciccio A, Pavlova N, Church G, Zhang W, **Kesari S**, Elledge SJ. Parallel Interaction Discovery Using Parallel Analysis of Translated ORFs (PLATO). *Nature Biotechnology* 2013; 31(4):331-4. PMID: 23503679

85. Shi G, Cui W, Benchimol M, Liu Y, Mattrey R, Mukthavaram R, **Kesari S**, Esener S, Simberg D. Isolation of Rare Tumor Cells from Blood Cells with Buoyant Immuno-Microbubbles. *PLoS ONE* 2013;8(3):e58017. PMID: 23516425

86. Nozawa A, Rivandi AH, **Kesari S**, Hoh CK. Glucose corrected standardized uptake value (SUV_{gluc}) in the evaluation of brain lesions with 18F-FDG PET. *European Journal of Nuclear Medicine and Molecular Imaging* 2013;40(7):997-1004. PMID: 23571761

87. Kothari PD, White NS, Farid N, Chung R, Kuperman JM, Girard HM, Shankaranarayanan A, **Kesari S**, MacDonald CR, Dale AM. Longitudinal Restriction Spectrum Imaging is Resistant to Pseudoresponse in Patients with High-Grade Gliomas Treated with Bevacizumab. *AJNR* 2013;34(9):1752-7. PMID: 23578667

88. Chao Y, Karmali PP, Mukthavaram R, **Kesari S**, Kouznetsova VL, Tsigelny IF, Simberg D. Direct recognition of superparamagnetic nanocrystals by macrophage scavenger receptor SR-AI. *ACS Nano* 2013;7(5):4289-98. PMID: 23614696

89. Shi G, Mukthavaram R, **Kesari S**, Simberg D. Distearoyl anchor-painted erythrocytes with prolonged ligand retention and circulation properties *in vivo*. *Advanced Healthcare Materials* 2013;3(1):142-8. PMID: 23798381

90. Zhang JP, Lee EQ, **Kesari S**, Doherty L, Muzikansky A, Wen PY, Drappatz J. Retrospective study of pemetrexed as salvage therapy for CNS lymphoma. *Journal of Neuro-Oncology* 2013;115(1):71-7. PMID: 23828279
91. Li L, Chakraborty S, Yang CR, Hatanpaa KJ, Cipher DJ, Puliyappadamba VT, Rehman A, Jiwani AJ, Mickey B, Madden C, Raisanen J, Burma S, Saha D, Wang Z, Pingle SC, **Kesari S**, Boothman DA, Habib AA. An EGFR wild type-EGFRvIII-HB-EGF feed-forward loop regulates the activation of EGFRvIII. *Oncogene* 2014;14;33(33):4253-64. PMID: 24077285
92. Liu X, Ide JL, Norton I, Marchionni MA, Ebling MC, Wang LY, Davis E, Sauvageot CM, **Kesari S**, Kellersberger KA, Easterling ML, Santagata S, Stuart DD, Alberta J, Agar JN, Stiles CD, Agar NYR. Molecular Imaging of Drug Transit Through the Blood-Brain Barrier with MALDI Mass Spectrometry Imaging. *Scientific Reports* 2013;3:2859. PMID: 24091529
93. Farid N, Almeida-Freitas DB, White NS, MacDonald CR, Muller KA, Vandenberg SR, **Kesari S**, Dale AM. Restriction Spectrum Imaging of Bevacizumab-Related Necrosis in a Patient with GBM. *Frontiers in Neuro-Oncology* 2013;3:258. PMID: 24137566
94. Muh CR, Joshi S, Singh AR, **Kesari S**, Durden DL, Makale MT. PTEN status mediates 2ME2 anti-tumor efficacy in preclinical glioblastoma models: Role of HIF1 α suppression. *Journal of Neuro-Oncology* 2014;116(1):89-97. PMID: 24162827
95. Mukthavaram R, Jiang P, Saklacha R, Simberg D, Bharati IS, Nomura N, Chao Y, Pastorino S, Pingle SC, Fogal V, Wrasidlo W, Makale M*, **Kesari S***. High-Efficiency Liposomal Encapsulation of a Tyrosine Kinase Inhibitor Leads to Improved *In Vivo* Toxicity and Tumor Response Profile. *International Journal of Nanomedicine* 2013;8:3991-4006. PMID: 24174874
***Senior/corresponding authors**
96. Akers JC, Ramakrishnan V, Kim R, Skog J, Nakano I, Pingle S, Kalinina J, **Kesari S**, Mao Y, Breakfield XO, Hochberg FH, Van Meir EG, Carter BS, Chen CC. miR-21 in the Extracellular Vesicles (EVs) of Cerebrospinal Fluid (CSF): A Platform for Glioblastoma Biomarker Development. *PLoS One* 2013;8(10):e78115. PMID: 24205116
97. Jiang P, Mukthavaram R, Chao Y, Summit IS, Fogal V, Pastorino S, Cong X, Nomura N, Gallagher M, Abbasi T, Vali S, Pingle SC, Makale M, **Kesari S***. Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs. *Journal of Translational Medicine* 2014;12(1):13. PMID: 24433351
***Senior/corresponding author**
98. Jiang P, Xue D, Zhang Y, Ye L, Liu Y, Makale M, **Kesari S**, Edgington TS, Liu C. The Extrinsic Coagulation Cascade and Tissue Factor Pathway Inhibitor in Macrophages: A Potential Therapeutic Opportunity for Atherosclerotic Thrombosis. *Thrombosis Research* 2014;133(4):657-66. PMID: 24485401
99. Nomura N, Pastorino S, Jiang P, Lambert G, Crawford JR, Gymnopoulos M, Piccioni D, Juarez T, Pingle SC, Makale M, **Kesari S***. Prostate specific membrane antigen (PSMA) expression in primary gliomas and breast cancer brain metastases. *Cancer Cell International* 2014;14(1):26. PMID: 24645697

***Senior/corresponding author**

100. Mukthavaram R, Shi S, **Kesari S**, Simberg D. Targeting and Depletion of Circulating Leukocytes and Cancer Cells by Lipophilic Antibody-Modified Erythrocytes. *Journal of Controlled Release* 2014;183C:146-53. PMID: 24685706

101. Pingle CS, Sultana Z, Pastorino S, Jiang P, Mukthavaram R, Chao Y, Bharati IS, Nomura N, Makale M, Abassi T, Kapoor S, Kumar A, Usmani S, Aggrawal A, Vali S, **Kesari S***. In Silico Deterministic Modeling Predicts Drug Sensitivity of Patient-Derived Cancer Cells. *Journal of Translational Medicine* 2014;12:128. PMID: 24884660

***Senior/corresponding author**

102. Scott BJ, van Vugt VA, Rush T, Brown T, Chen CC, Carter BS, Schwab R, Fanta P, Helsten T, Bazhenova L, Parker B, Pingle S, Saria MG, Brown BD, Piccioni DE, **Kesari S***. Concurrent intrathecal methotrexate and liposomal cytarabine for leptomeningeal metastasis from solid tumors: a retrospective cohort study. *Journal of Neuro-Oncology* 2014;119(2):361-8. PMID: 24942463

***Senior/corresponding author**

103. Jiang P, Mukthavaram R, Chao Y, Nomura N, Summit I, Fogal V, Pastorino S, Teng D, Cong X, Pingle SC, Kapoor S, Shetty K, Aggrawal A, Vali S, Abbasi T, Chien S, **Kesari S***. In Vitro and In Vivo Anti-Cancer Effects of Mevalonate Pathway Modulation on Human Cancer Cells. *British Journal of Cancer* 2014; (**in press**). PMID: 25093497

***Senior/corresponding author**

104. Farid N, Almeida-Freitas DB, White NS, McDonald CR, Kuperman JM, Almutairi AA, Muller KA, Vandenberg SR, **Kesari S**, Dale AM. Combining Diffusion and Perfusion Differentiates Tumor from Bevacizumab-Related Imaging Abnormality (BRIA). *J. Neuro-Oncology* 2014;120(3):539-46. PMID: 25135423

105. Jung JY, Hirata GA, Gundiah G, Derenzo S, Wrasidilo W, **Kesari S**, Makale MT, McKittrick J. Identification and development of nanoscintillators for biotechnology applications. *Journal of Luminescence* 2014;154:569-77. PMID:

106. Van Vugt VA, Piccioni DE, Brown BD, Brown T, Saria MG, Juarez T, **Kesari S***. Retrospective analysis of safety and feasibility of a 3 days on/ 11 days off temozolomide dosing regimen in recurrent adult malignant gliomas. *CNS Oncology* 2014;3(4):257-65. PMID: 25286037

***Senior/corresponding author**

107. Hesselink JR, Barkovich MJ, Seibert TM, Farid N, Muller KA, Murphy KT, **Kesari S**. Bevacizumab – Radiation Combination Produces Restricted Diffusion on Brain MRI. *CNS Oncology* 2014;3(5):329-35. PMID: 25363005

108. Schiff D, **Kesari S**, DeGroot JF, Mikkelsen T, Drappatz J, Coyle T, Fichtel L, Silver B, Walters I, Reardon D. Phase 2 Study of CT-322, a Targeted Biologic Inhibitor of VEGFR-2 Based on a Domain of Human Fibronectin, in Recurrent Glioblastoma. *Investigational New Drugs* 2015;33(1):247-53. PMID: 25388940

109. Fogal V, Babic I, Chao Y, Pastorino S, Mukthavaram R, Jiang P, Cho Y, Pingle SC, Crawford JR, Piccioni D, **Kesari S***. Mitochondrial p32 is upregulated in Myc expressing brain cancers and mediates glutamine addiction. *Oncotarget* 2015;6(2):1157-70. PMID: 25528767
***Senior/corresponding author**

110. Tsigelny IF*, Kouznetsova VL, Jiang P, Pingle SC, **Kesari S***. Hierarchical control of coherent gene clusters defines the molecular mechanisms of glioblastoma. *Molecular BioSystems* 2015;11(4):1012-28. PMID: 25648506
***Co-Senior/corresponding author**

111. Kato S, Schwaederle M, Daniels GA, Piccioni D, **Kesari S**, Bazhenova L, Shimabukuro K, Parker BA, Fanta P, Kurzrock R. Cyclin-Dependent Kinase Pathway Aberrations in Diverse Malignancies: Clinical and Molecular Characteristics. *Cell Cycle* 2015; (**in press**). PMID: 25695927

112. Nozawa A, Rivandi AH, Kanematsu M, Hoshi H, Piccionni D, **Kesari S**, Hoh CK. Glucose-corrected standardized uptake value in the differentiation of high grade glioma versus post-treatment changes. *Nuclear Medicine Communications*. 2015; (**in press**). PMID: 25714806

113. Le AP, Huang Y, Pingle SC, **Kesari S**, Wang H, Yong RL, Zou H, Friedel RH. Plexin-B2 promotes invasive growth of malignant glioma. *Oncotarget* 2015; (**in press**). PMID: 25762646

114. Ichim TE, Li S, Ma H, Yurova YV, Szymanski JS, Patel AN, **Kesari S**, Min WP, Wagner SC. Induction of Tumor Inhibitory Anti-Angiogenic Response Through Immunization with Interferon Gamma Primed Placental Endothelial Cells: ValloVax. *Journal of Translational Medicine* 2015;13(1):441. PMID: 25779148

115. Jackman DM*, Cioffredi LA, Jacobs L, Sharmeen F, Morse LJ, Lucca J, Plotkin SR, Marcoux JP, Rabin MS, Lynch TJ, Johnson BE, **Kesari S***. A Phase I study of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancer. *Oncotarget* 2014;6(6):4527-36. PMID: 25784657
***Co-Senior/corresponding author**

116. Jadin L, Pastorino S, Symons R, Nomura N, Jiang P, Juarez T, Makale M, **Kesari S***. Hylauronidase expression in gliomas and breast cancer brain metastases. *Annals of Translational Medicine* 2015; (**in press**). PMID:
***Senior/corresponding author**

117. Schwaederle M, Daniels G, Piccioni D, Kesari S, Bazhenova L, Shimabukuro K, Parker BA, Fanta P, Kurzrock R. Next Generation Sequencing Demonstrates Association between Tumor Suppressor Gene Aberrations and Poor Outcome in Patients with Cancer. 2015; Cell Cycle (in review). PMID:

118. Elinzano H, Glantz M, Mrugala M, Kesari S, Kim L, Jeyapalan S, Pan E, Yunus S, Coyle T, Kinsella T, Evans D, Mantripraga K, Boxerman J, Dipetrillo J, Donahue J, Hebda N, Mitchell K, Rosati K, Safran H. PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma

Without MGMT Methylation - A Randomized Phase II Study: BrUOG 244. 2015; (in review). PMID:

119. Wang X, Zhang C, Yan X, Lan B, Wei C, Cao X, Yao J, Zhou T, Zhou M, Liu Q, Jiang B, Wang J, Jiang P, **Kesari S***, Guo F. A novel bioavailable BH3 mimetic efficiently inhibits colon cancer via cascade effects of mitochondria. 2015; CCR (in review). PMID:

***Senior/corresponding author**

120. Xiu J, Piccioni D, Juarez T, Pingle SC, Hu J, Rudnick J, Fink K, Spetzer DB, Maney T, Ghazalpour A, Bender R, Gatalica Z, Reddy S, Sanai N, Idhahbi A, Glantz M, **Kesari S***. Multi-platform Molecular Profiling of a Large Cohort of Gliomas Reveals Potential Therapeutic Strategies. Nature Scientific reports 2015; (in review). PMID:

***Senior/corresponding author**

121. Tsigelny IF, Mukthavaram R, Kouznetsova VL, Chao YS, Babic I, Nurmammadov E, Pastorino S, Jiang P, Pingle SC, Wrasidlo W, Makale M, **Kesari S***. Multiple spatially related pharmacophores define small molecules for inhibition of OLIG2 in glioblastoma. PNAS 2015; (submitted). PMID:

***Senior/corresponding author**

122. Fichtenholtz A, Goldberg ME, Elvin J, Frampton GM, Ali SM, Ross JS, Neumann E, Piccioni D, **Kesari S**, Stephens PJ, Chmielecki J. Integrated genomic analysis of glial tumors and the potential for targeted therapy approaches in defined patient subsets. Science Translational Medicine 2015; (submitted). PMID:

123. Mukthavaram R, Ouyang X, Saklacha R, Jiang P, Nomura N, Pingle SC, Guo F, Makale M, **Kesari S***. Effect of the JAK2/STAT3 inhibitor TG101209 on human glioblastoma tumorspheres. 2015; JTM (in review). PMID

***Senior/corresponding author**

124. **Kesari S***, Demuth T, Chinnayan P, Butowski N, Groves MD, Blackman S, Giannotti M, LoRusso P, Krop I, Wen P. Phase II Study of the Gamma Secretase (Notch) inhibitor MK-0752 in progressive gliomas. J. Clinical Oncology 2015; (submitted). PMID:

***Senior/corresponding author**

125. Corle C, Rush T, Saria MG, **Kesari S***. Improved Outcomes of Patients with Glioblastoma in NCI-Designated Clinical Cancer Centers. JNCI 2015; (submitted). PMID:

***Senior/corresponding author**

126. Rush T, Lindsay S, Lemus H, **Kesari S***. Improved Survival of Patients with Nonmalignant, Intracranial Meningiomas at NCI-Designated Clinical Cancer Centers Using the California Cancer Registry. JNCI 2015; (submitted). PMID:

***Senior/corresponding author**

127. Pastorino S, Chao Y, Borrás AM, **Kesari S***. Platelet derived growth factor receptor alpha predicts response to kinase inhibitors in glioblastoma patients. 2015; (in preparation). PMID:

***Senior/corresponding author**

128. Pingle S, Juarez T, Pastorino S, Jiang P, Barnachea L, Bazhenova L, Mitchell W, Tucker C, Yang T, Brown T, Saria M, Makale M, Piccioni D, Pingle SC, **Kesari S***. Cerebrospinal fluid pharmacokinetics of high-dose erlotinib regimens in brain cancer patients. *STM* 2015; (**in review**). PMID:

***Senior/corresponding author**

129. Hope TR, White NS, Kuperman JM, Chao Y, Nomura N, Bartch H, Schenker N, Rakov-Penner R, Bussel R, **Kesari S**, Ajournerud A, Dale AM. Direct Imaging of Tumor Cells Using Diffusion-Time Dependent Contrast. 2015; (**submitted**).: PMID:

130. Sluzmaier FJ, Precht AM, Geerts D, Matter ML, Jiang P, **Kesari S**, Ramos J. A PEA15 and RSK2 complex regulates glioblastoma cell motility and invasion. *Oncogene* 2015; (**in review**). PMID:

131. Ibsen S, Sonnenberg A, Ibsen C, Mukthavaram R, Yeh Y, Ortac I, Manouchehri S, **Kesari S**, Esener S, Heller M. Recovery of Drug Delivery Nanoparticles from Human Plasma using an Electrokinetic Platform Technology. *PNAS* 2015; (**submitted**). PMID:

132. Gay LJ, Day J, LeBoeuf SE, Ritland M, **Kesari S**, Ruggeri ZM, Ruf W, Felding-Habermann B. Brain Metastasis Depends on Tumor Cell Initiated Coagulation and Tissue Factor Signaling. *Nature Medicine* 2015; (**submitted**). PMID:

133. Minetto MA, Caresio C, D'Angelo V, Costale A, Bertinaria M, Arvat E, **Kesari S**. Diagnostic work-up in steroid myopathy: case study and literature review. 2015; (**submitted**). PMID:

134. Scott BJ, Piccioni D, **Kesari S***. Leptomeningeal Metastasis in Lung Cancer – A Systematic Review. *CNS Oncology* 2014; (**in preparation**). PMID:

***Senior/corresponding author**

Reviews, Chapters, and Editorials:

1. Trojanowski JQ, Kleppner SR, Hartley RS, Miyazono M, Fraser NW, **Kesari S**, Lee VM. Transfectable and transplantable postmitotic human neurons: A potential "platform" for gene therapy of nervous system diseases. *Experimental Neurology* 1997;144(1):92-7. PMID: 9126157
2. **Kesari S**, Batchelor T. Leptomeningeal metastasis. *Neurologic Clinics* 2003;21(1):25-66. PMID: 12690644
3. Wen PY, **Kesari S**. Neurologic complications of chemotherapy. In: Gilman S, editor. *MedLink Neurology*. San Diego: MedLink Corporation. Available at www.medlink.com. Accessed April 1, 2003.
4. **Kesari S**. Paraneoplastic neurologic syndromes in women's cancer [review]. *J Watch Neurol*. October 2003. Review of Rojas-Marcos I et al. Spectrum of paraneoplastic neurologic disorders in women with breast and gynecologic cancer. *Medicine* 2003;May;82:216-23.

5. **Kesari S.** Update on paraneoplastic neurological syndromes [review]. *J Watch Neurol.* February 2004. Review of Darnell & Posner, Paraneoplastic neurologic syndromes. *NEJM* 2003; Oct;349(16):1543-54.
6. **Kesari S,** Wen PY. Neurooncology. In: Samuels M, editor. *Manual of Neurologic Therapeutics*, 7th edition, Philadelphia: Lippincott Williams & Wilkins; 2004. p. 115-178.
7. Wen PY, **Kesari S.** Malignant gliomas. *Current Neurology and Neuroscience Reports* 2004;4(3):218-27. PMID: 15102348
8. Wen PY, **Kesari S,** Hsu L, De Girolami U. Brain Tumors. In: Griggs RC, Joynt RJ. editors. *Baker and Joynt's Clinical Neurology CD-ROM*, Philadelphia: Lippincott Williams & Wilkins; 2004.
9. Mrugala MM, **Kesari S,** Ramakrishna N, Wen PY. Therapy for recurrent malignant gliomas. *Expert Review of Anticancer Therapy* 2004;4(5):759-82. PMID: 15485312
10. **Kesari S,** Wen PY. Neuroprotective effect of vitamin E supplementation [commentary]. *Neurology.* January 11, 2005; Commentary on Argyriou et al., Vitamin E For Prophylaxis Against Chemotherapy-Induced Neuropathy: A Randomised Controlled Trial. *Neurology* 2005 Jan;64:26-31.
11. **Kesari S,** Ramakrishna N, Sauvageot C, Stiles CD, Wen PY. Targeted molecular therapy of malignant gliomas. *Current Neurology and Neuroscience Reports* 2005;5(3):186-97. PMID: 15865884
12. Norden AD, **Kesari S***. Pituitary adenoma. In: Gilman S, editor. *MedLink Neurology.* San Diego: MedLink Corporation. Available at www.medlink.com. Accessed November 11, 2005.
***Senior/corresponding author**
13. Norden AD, Wen PY, **Kesari S***. Brain metastases. *Current Opinion in Neurology* 2005;18(6):654-61. PMID: 16280676
***Senior/corresponding author**
14. **Kesari S,** Ramakrishna N, Sauvageot C, Stiles CD, Wen PY. Targeted molecular therapy of malignant gliomas. *Current Oncology Reports* 2006;8(1):58-70. PMID: 16464405
15. Chi, A, **Kesari S***. POEMS syndrome. In: Gilman S, editor. *MedLink Neurology.* San Diego: MedLink Corporation. Available at www.medlink.com. Accessed February 1, 2006.
16. Wen PY, **Kesari S,** Drappatz J. Malignant gliomas: Strategies to increase the effectiveness of targeted molecular treatment. *Expert Review of Anticancer Therapy* 2006;6(5):733-54. PMID: 16759164
17. **Kesari S***, Santagata S. Germinoma. In: Gilman S, editor. *MedLink Neurology.* San Diego: MedLink Corporation. Available at www.medlink.com. Accessed March 29, 2006.
***Senior/corresponding author**

18. Wen PY, **Kesari S**, Grier J. Neurologic complications of chemotherapy. In: Gilman S, editor. MedLink Neurology. San Diego: MedLink Corporation. Available at www.medlink.com. Accessed June 15, 2006.
19. Wen PY, Schiff D, **Kesari S**, Drappatz J, Gigas DC, Doherty L. Medical management of patients with brain tumors. *Journal of Neuro-Oncology* 2006;80(3):313-32. PMID: 16807780
20. **Kesari S**, Stiles CD. The Bad Seed: PDGF receptors link adult neural progenitors to glioma stem cells. *Neuron* 2006;51(2):151-3. PMID: 16846849
21. Quant E, **Kesari S***. Primary central nervous system lymphoma. In: Gilman S, editor. MedLink Neurology. San Diego: MedLink Corporation. Available at www.medlink.com. Accessed August 13, 2006.
***Senior/corresponding author**
22. Monje M, **Kesari S***. Sequelae of treatments of CNS tumors. In: Gilman S, editor. MedLink Neurology. San Diego: MedLink Corporation. Available at www.medlink.com. Accessed December 4, 2006.
***Senior/corresponding author**
23. Norden AD, **Kesari S***. Pituitary adenoma. In: Gilman S, editor. MedLink Neurology. San Diego: MedLink Corporation. Available at www.medlink.com. Accessed December 10, 2006.
***Senior/corresponding author**
24. Chheda M, **Kesari S**, Wen PY. Uncommon Brain Tumors. In: Rose B (editor), UpToDate, Waltham, MA: UpToDate. Available at www.uptodate.com, Accessed January 4, 2007.
25. **Kesari S***, Santagata S. Germinoma. In: Gilman S, editor. MedLink Neurology. San Diego: MedLink Corporation. Available at www.medlink.com. Accessed January 20, 2007.
***Senior/corresponding author**
26. **Kesari S**, Jackson-Grusby L, Stiles CD. 'Smad'eningly erratic: target gene methylation determines whether TGFb promotes or suppresses malignant glioma. *Developmental Cell* 2007;12(3):324-5. PMID: 17336898
27. **Kesari S**. Low-Grade Gliomas: Natural History and Chemotherapy Response [review]. *J Watch Neurol*. July 31, 2007. Review of Ricard D, et al, Dynamic history of low-grade gliomas before and after temozolomide treatment. *Ann Neurol* 2007;61:484-90.
28. Sauvageot CM, **Kesari S**, Stiles CD. Molecular pathogenesis of adult brain tumors and the role of stem cells. *Neurologic Clinics* 2007;25(4):891-924. PMID: 17964020
29. Drappatz J, Schiff D, **Kesari S**, Norden AD, Wen PY. Medical management of brain tumor patients. *Neurologic Clinics* 2007;25(4):1035-71. PMID: 17964025
30. Grewal J, **Kesari S***. Breast cancer surface receptors predict risk of developing brain metastasis and subsequent prognosis [editorial]. *Breast Cancer Research* 2008;10(2):104. PMID: 18373884

***Senior/corresponding author**

31. **Kesari S***, Paleologos N, Vick N. Corticosteroids in neuro-oncology. In: Cancer Neurology in Clinical Practice: Neurologic Complications of Cancer and its Treatment. 2nd edition. Schiff D, Kesari S, Wen PY, (ed) Totowa, New Jersey. Humana Press 2008, 47-56.

***Senior/corresponding author**

32. **Kesari S***, Kunschner LJ. Neurological complications of sarcoma. In: Cancer Neurology in Clinical Practice: Neurologic Complications of Cancer and its Treatment. 2nd edition. Schiff D, Kesari S, Wen PY (ed) Totowa, New Jersey. Humana Press 2008, 495-506.

***Senior/corresponding author**

33. Dietrich J, Imitola J, **Kesari S***. Mechanisms of disease: the role of stem cells in the biology and treatment of gliomas. Nature Clinical Practice Oncology 2008;5(7):393-404. PMID: 18521117

***Senior/corresponding author**

34. **Kesari S**. Meningitis in Cancer Patients: Changes Accompany Medical Advances. [review]. J Watch Neurol. August 31, 2008. Review of Safdieh JE, et al. Bacterial and fungal meningitis in patients with cancer. Neurology 2008 Mar 18;70:943-7.

35. Wen PY, **Kesari S**. Malignant gliomas in adults. New England Journal of Medicine 2008;359(5):492-507. PMID: 18669428

36. Grewal J, Grewal HK, **Kesari S***. Brain Tumors. In: Neurology review for psychiatrists. Savitz SI and Ronthal M (eds). Lippincott Williams & Wilkins. 2009, 283-304.

***Senior/corresponding author**

37. **Kesari S**. A novel target for glioblastoma therapy. [review]. J Watch Neurol. July 31, 2009. Review of Yan H, et al. IDH1 and IDH2 mutations in gliomas. New England Journal of Medicine 2009 Feb 19;360:765-73.

38. Glantz M, **Kesari S**, Recht L, Fleischhack G, Van Horn A. Understanding the origins of gliomas and developing novel therapies: Cerebrospinal fluid and subventricular zone interplay. Seminars in Oncology 2009; 36(4 Suppl 2):S17-24. PMID: 19660679

39. Grewal J, Grewal HK, **Kesari S***. POEMS syndrome. In: Gilman S, editor. MedLink Neurology. San Diego: MedLink Corporation. Available at www.medlink.com. Accessed September 14, 2009.

***Senior/corresponding author**

40. Grewal J, Duic JP, **Kesari S***. Spinal ependymoma. In: Gilman S, editor. MedLink Neurology. San Diego: MedLink Corporation. Available at www.medlink.com. Accessed September 15, 2009.

***Senior/corresponding author**

41. Duic JP, Grewal J, **Kesari S***. Germinoma. In: Gilman S, editor. MedLink Neurology. San Diego: MedLink Corporation. Available at www.medlink.com. Accessed September 16, 2009.

***Senior/corresponding author**

42. Dietrich J, **Kesari S***. Effect of cancer treatment on neural stem and progenitor cells. In: Late Effects of Treatment for Brain Tumors. Goldman S and Turner CD (eds). Cancer Treat Res 2009;150:81-95. PMID: 19834663

***Senior/corresponding author**

43. Grewal J, Tessler L, **Kesari S***. Pituitary adenoma. In: Gilman S, editor. MedLink Neurology. San Diego: MedLink Corporation. Available at www.medlink.com. Accessed October 28, 2009.

***Senior/corresponding author**

44. Dunbar EM, **Kesari S***. Low-grade Gliomas in Older Patients: Older adults have inferior outcomes compared with younger adults. [summary and comment]. J Watch Neurol. December 2010. Review of Kaloshi G, et al, Supratentorial low-grade gliomas in older patients. Neurology 2009;73:2093.

***Senior/corresponding author**

45. Grewal J, **Kesari S***. Leptomeningeal metastases. In: Gilman S, editor. MedLink Neurology. San Diego: MedLink Corporation. Available at www.medlink.com. Accessed August 1, 2010.

46. Saar BG, Freudiger CW, Xu X, Huttner A, **Kesari S**, Young G, Xie XS. Coherent Raman Tissue Imaging in the Brain. In: Yuste (ed). Imaging: A Laboratory Manual. CSHL Press, Cold Spring Harbor, 2011.

47. **Kesari S**. Acute headache. In: Mushlin S, Greene HL (eds). Decision making in medicine: An algorithmic approach. 3rd ed. St. Louis: Mosby; 2010. 402-3.

48. **Kesari S**. Chronic headache. In: Mushlin S, Greene HL (eds). Decision making in medicine: An algorithmic approach. 3rd ed. St. Louis: Mosby; 2010. 403-7.

49. **Kesari S**. Disturbances of smell and taste. In: Mushlin S, Greene HL (eds). Decision making in medicine: An algorithmic approach. 3rd ed. St. Louis: Mosby; 2010. p. 458-9.

50. Dietrich J, Diamond EL, **Kesari S***. Glioma stem cell signaling: Therapeutic opportunities and challenges. Expert Review of Anticancer Therapy 2010;10(5):709-22. PMID: 20470003

***Senior/corresponding author**

51. Dunbar EM, **Kesari S***. Tubular Vasculogenic Mimicry in Glioblastoma: Glioblastoma cells can make their own blood vessels. [summary and comment]. J Watch Neurol. December 2010. Review of El Hallani S, et al, A new alternative mechanism in glioblastoma vascularization: Tubular vasculogenic mimicry. Brain 2010;133:973.

***Senior/corresponding author**

52. Dunbar EM, **Kesari S***. Gliomas: Current issues in diagnosis and treatment. Current Medical Imaging Reviews 2010;6(4):285-294. PMID: ???

***Senior/corresponding author**

53. **Kesari S**, Wen PY. Neurooncology. In: Samuels MA, Ropper A (eds). Samuel's Manual of Neurologic Therapeutics, 8th edition, Philadelphia: Lippincott Williams & Wilkins; 2010. p. 114-170.
54. **Kesari S**, Bota DA. Fos-related antigen-1 (Fra-1) is a regulator of glioma cell malignant phenotype. 2011;11(3):307-10. PMID: 21242721
55. Mou X, **Kesari S**, Wen PY, Huang X. Crude Drugs as Anticancer Agents. Int J Clin Exp Med. 2011;4(1):17-25. PMID: 21394282
56. Dietrich J, Rao K, Pastorino S, **Kesari S***. Corticosteroids in brain cancer patients: benefits and pitfalls. Expert Rev Clin Pharmacol 2011;4(2):233-42. PMID: 21666852
***Senior/corresponding author**
57. Grewal J, Saria MG, **Kesari S**. Novel approaches to treating leptomeningeal metastases. J Neuro-oncology 2011;106(2):225-234. PMID: 21874597
58. Grewal J, Grewal HK, **Kesari S**. Cerebrovascular complications of cancer. In: Gilman S, editor. MedLink Neurology. San Diego: MedLink Corporation. Available at www.medlink.com. Accessed February 1, 2011.
59. Grewal J, Grewal HK, **Kesari S**. Spinal astrocytoma. In: Gilman S, editor. MedLink Neurology. San Diego: MedLink Corporation. Available at www.medlink.com. Accessed February 1, 2011.
60. Grewal J, Grewal HK, **Kesari S**. POEMS syndrome. In: Gilman S, editor. MedLink Neurology. San Diego: MedLink Corporation. Available at www.medlink.com. Accessed March 26, 2011.
61. Grewal J, **Kesari S**. Primary central nervous system lymphoma. In: Gilman S, editor. MedLink Neurology. San Diego: MedLink Corporation. Available at www.medlink.com. Accessed April 1, 2011.
62. Grewal J, **Kesari S**. Sequelae of treatments of CNS tumors. In: Gilman S, editor. MedLink Neurology. San Diego: MedLink Corporation. Available at www.medlink.com. Accessed April 1, 2011.
63. Grewal J, Tessler L, **Kesari S**. Adenoma. In: Gilman S, editor. MedLink Neurology. San Diego: MedLink Corporation. Available at www.medlink.com. Accessed April 6, 2011.
64. Grewal J, Duic JP, **Kesari S**. Spinal ependymoma. In: Gilman S, editor. MedLink Neurology. San Diego: MedLink Corporation. Available at www.medlink.com. Accessed June 17, 2011.
65. Duic JP, Grewal J, **Kesari S**. Germinoma. In: Gilman S, editor. MedLink Neurology. San Diego: MedLink Corporation. Available at www.medlink.com. Accessed July 29, 2011.

66. **Kesari S**, Advani SJ, Lawson JD, Kahle KT, Ng K, Carter B, Chen CC. DNA damage response and repair: Insights into strategies for radiation sensitization of gliomas. *Future Oncology* 2011;7(11):1335-46. PMID: 22044206
67. Kim RY, Mahta A, **Kesari S** (2011). Glioma stem cells, *Cancer Stem Cells-The Cutting Edge*, Stanley Shostak (Ed.), ISBN: 978-953-307-580-8, InTech, Available from: <http://www.intechopen.com/articles/show/title/glioma-stem-cells>
68. Ng K, **Kesari S**, Carter B, Chen CC (2011). Molecular Etiology of Glioblastomas: Implication of Genomic Profiling From the Cancer Genome Atlas Project, *Glioma-Exploring Its Biology and Practical Relevance*, Anirban Ghosh (Ed.), ISBN: 978-953-307-379-8, InTech, Available from: <http://www.intechopen.com/articles/show/title/molecular-etiology-of-glioblastomas-implication-of-genomic-profiling-from-the-cancer-genome-atlas-pr>
69. Lawson JD, Kahle KT, Ng K, Carter B, **Kesari S**, Chen CC (2011). DNA Damage Response and Repair: Insights into Strategies for Radiation Sensitization, *Selected Topics in DNA Repair*, Clark C. Chen (Ed.), ISBN: 978-953-307-606-5, InTech, Available from: <http://www.intechopen.com/articles/show/title/dna-damage-response-and-repair-insights-into-strategies-for-radiation-sensitization>
70. Jiri B Jr., Ng K, Jiri B Sr., **Kesari S**, Carter B, Chen CC (2011). Key Principles in Glioblastoma Therapy. *Advances in the Biology, Imaging and Therapies for Glioblastoma*, Clark C. Chen (Ed.), ISBN: 978-953-307-284-5, InTech, Available from: <http://www.intechopen.com/articles/show/title/key-principles-in-glioblastoma-therapy>
71. **Kesari S**. Understanding Glioblastoma Tumor Biology: the potential to improve current diagnosis and treatments. *Seminars in Oncology* 2011;38(s4):S2-10. PMID: 22078644
72. Grewal J, Saria M, Grewal HK, **Kesari S***. Neoplastic meningitis resulting from hematological malignancies: Pharmacokinetic considerations and maximizing outcome. *Clin Investig* 2011;1(10):1391-1402. PMID: 22396850
***Senior/corresponding author**
73. Ng K, Kim R, **Kesari S**, Carter B, Chen CC. Genomic Profiling of glioblastoma: convergence of fundamental biologic tenets and novel insights. *Journal of Neuro-Oncology* 2012;107(1):1-2. PMID: 22002595
74. Hu J, **Kesari S***. The molecular basis for novel therapies. *Cancer Journal* 2012; 18(1):32-9. PMID: 22290255
***Senior/corresponding author**
75. Corle C, Makale M, **Kesari S***. Cell phones and glioma risk: A review of the evidence. *J Neuro-oncology*. 2012;106(1):1-13. PMID: 21853424
***Senior/corresponding author**
76. Hu J, **Kesari S***. Strategies for overcoming the blood-brain barrier for the treatment of brain metastases. *CNS Oncology* 2013;2(1):87-98. PMID: 25054359
***Senior/corresponding author**

77. Scott BJ, **Kesari S***. Leptomeningeal Metastases in Breast Cancer. American Journal of Cancer Research. 2013;3(2):117-26. PMID: 23593536

***Senior/corresponding author**

78. Davis DL, **Kesari S**, Soskolne CL, Miller AB, Stein Y. Swedish review strengthens grounds for concluding that radiation from cellular and cordless phones is a probable human carcinogen. Pathophysiology 2013;20(2):123-9. PMID: 23664410

79. Piccioni DE, **Kesari S***. Clinical Trials of Viral Therapy for Malignant Gliomas. Expert Review of Anticancer Therapy 2013;13(11):1297-305. PMID: 24138481

***Senior/corresponding author**

135. Tsigelny IF*, Kouznetsova VL, Pingle SC, **Kesari S***. bHLH Transcription Factors Inhibitors for Cancer Therapy: General Features for Insilico Drug Design. Current Medicinal Chemistry 2014; (**in press**). PMID: 24735358

***Co-corresponding author**

80. Saar BG, Freudiger CW, Xu X, Huttner A, **Kesari S**, Young G, Xie XS. Coherent Raman Tissue Imaging in the Brain. Cold Spring Harbor Protocols 2014;2014(5) PMID: 24786507

81. White NS, McDonald CR, Farid N, Kuperman J, Karow D, Schenker-Ahemd NM, Bartch H, Rakow-Penner R, Holland D, Shabaik A, Bjørnerud A, Hope T, Hattangadi-Gluth J, Liss M, Parsons JK, Chen CC, Raman S, Margolis S, Reiter RE, Marks L, **Kesari S**, Mundt AJ, Kaine CJ, Carter BS, Bradley WG, Dale AM. Diffusion-weighted imaging in cancer: Physical foundations and applications of restriction spectrum imaging. Cancer Research 2014;74(17):4638-52. PMID: 25183788

82. Lyday B, Chen T, **Kesari S**, Minev B. Overcoming Tumor Immune Evasion with an Unique Arbovirus. JTM 2015;13(1):3. PMID: 25592450

83. Patel KS, **Kesari S**, Advani SJ, Lawson JD, Carter B, Chen CC. DNA damage response and repair: rationale for radio-sensitizing agent use in glioblastomas. Proteomes 2014; PMID:

84. Morgan LL, **Kesari S**, Davis DL. Why Children Absorb More Microwave Radiation than Adults: The Consequences. Journal of Microscopy and Ultrastructure 2014;2:197-204. PMID:

136. Makale M, **Kesari S***. Cell phones and glioma risk: An Update. EANO. 2015;. PMID:

***Senior/corresponding author**

137. Alentorn A, Idbaih A, **Kesari S***. Molecular profiling of gliomas: potential therapeutic implications. ERAT. 2015;. PMID:

***Senior/corresponding author**

138. Stegh AH, Chalastanis A, Pingle SC, Kesari S. Targeting cell death mechanisms to overcome therapeutic resistance in malignant gliomas. Nature Reviews 2015; (**submitted**). PMID:

85. Dunbar EM, Kalani R, **Kesari S***. *Neurological complications of corticosteroids in cancer therapy. In: Neurologic Complications of Cancer Therapy. 1st edition. Quant E, Schiff D, Wen PY (eds) City, State. Demos Medical Publishing 2012, xxx.*

***Senior/corresponding author**

86. Martuscello RT, Renyolds B, **Kesari S***. *Glioma Stem Cells. In: Translational Neuroscience. Tuszynski M. (ed). Springer 2015*

***Senior/corresponding author**

87. Hu J, **Kesari S***. *General aspects of chemotherapy. In: Schiff D (eds). Neuro-oncology. 1st ed. St. Louis: Wiley-Blackwell; 2011.*

***Senior/corresponding author**

88. Hu J, **Kesari S***. *Novel and prospective chemotherapeutic regimens for management of gliomas. In: Chernov MF, Muragaki Y, Kesari S, McCutcheon IE (eds). Contemporary Management of Intracranial Gliomas. Series in Progress in Neurological Surgery. Karger Press Totowa, NJ 2015*

***Senior/corresponding author**

89. Scott B, **Kesari S***. *Brain Cancer – The New Frontiers. In: Latifi R, Rhee P, Gruessner R (eds). Technological Advances in Surgery, Trauma, and Critical Care. Springer Science + Business Media. 2015*

***Senior/corresponding author**

Books, Monographs, and Text Books:

1. **Kesari S**. Digitally altered photographs depicting different manifestations of visual aura. In: Merck & Co. Monographs in Medicine: A Study of Migraine. New Jersey: Whitehouse Station; 2005. p. 38.

2. Norden AD, **Kesari S***. Cancer neurology: Primary and metastatic brain tumors. In: Atri A, Milligan TA, editors. Hospital physician neurology board review manual. Wayne (PA): Turner White Communications; 2006:10(Pt 3):1-16.

***Senior/corresponding author**

3. Norden AD, **Kesari S***. Cancer neurology: Primary CNS lymphoma, paraneoplastic syndromes, and pituitary adenoma. In: Atri A, Milligan TA, editors. Hospital physician neurology board review manual. Wayne (PA): Turner White Communications; 2007:11(Pt 1):1-16.

***Senior/corresponding author**

4. Schiff D, **Kesari S**, Wen PY (eds). *Cancer Neurology in Clinical Practice. 2nd edition. Humana Press Totowa, NJ 2008.*

5. Saria M, **Kesari S** (eds). *Focusing on Tumors: Meningiomas: Published by the American Brain Tumor Association, 2011.*

6. Grewal J, Grewal HK, **Kesari S***. Primary brain tumors. In: Skarin AT, editor. Hospital Physician Oncology Board Review Manual. Wayne (PA): Turner White Communications; 2013:10(Pt 2):1-19.

***Senior/corresponding author**

7. Grewal J, Grewal HK, **Kesari S***. Metastatic brain tumors. In: Skarin AT, editor. Hospital Physician Oncology Board Review Manual. Wayne (PA): Turner White Communications; 2013:10(Pt 4):1-16.

***Senior/corresponding author**

8. *Chernov MF, Muragaki Y, Kesari S, McCutcheon IE (eds). Contemporary Management of Intracranial Gliomas. Series in Progress in Neurological Surgery. Karger Press Totowa, NJ 2015.*

Clinical Communications:

1. **Kesari S***, Bundock EA. Punched-out skull. Archives of Neurology 2004;61(6):958-9. PMID: 15210540

***Senior/corresponding author**

2. **Kesari S***. Digital rendition of visual migraines. Archives of Neurology 2004;61(9):1464-5. PMID: 15364697

***Senior/corresponding author**

3. Gerin F, Baloglu O, Morgan JA, **Kesari S***. Central nervous system metastases from imatinib mesylate resistant gastrointestinal stromal tumor. Journal of Neuro-Oncology 2007;82(2):227-8. PMID: 17106648

***Senior/corresponding author**

4. Santagata S, **Kesari S**, Black PM, Chan JA. Anaplastic variant of medulloblastoma mimicking a vestibular schwannoma. Journal of Neuro-Oncology 2007;81(1):49-51. PMID: 17146596

5. Narin O, Drappatz J, Doherty LM, Wen PY, **Kesari S***. Cerebrospinal fluid spread of anaplastic glioma. Journal of Clinical Oncology 2007;25(5):596-7. PMID: 17290068

***Senior/corresponding author**

6. Monje ML, Ramakrishna NR, Young G, Drappatz J, Doherty LM, Wen PY, **Kesari S***. Durable response of a radiation-induced, high-grade cerebellar glioma to temozolomide. Journal of Neuro-Oncology 2007; 84(2):179-83. PMID: 17332945

***Senior/corresponding author**

7. Chheda MG, Drappatz J, Greenberger NJ, **Kesari S**, Weiss SE, Gigas DC, Doherty LM, Wen PY. Hepatitis B reactivation during glioblastoma treatment with temozolomide: A cautionary note. Neurology 2007;68(12):955-6. PMID: 17372135

8. Wabulya A, Imitola J, Santagata S, **Kesari S***. Mycosis fungoides with leptomeningeal involvement. Journal of Clinical Oncology 2007;25(35):5658-61. PMID: 18065739

***Senior/corresponding author**

9. Akar S, Drappatz J, Hsu L, Blinder RA, Black PM, **Kesari S***. Hypertrophic olivary degeneration after resection of a cerebellar tumor. *Journal of Neuro-Oncology* 2008;87(3):341-5. PMID: 18217209

***Senior/corresponding author**

10. Saad A, Tuli S, Ali EN, Houtchens M, Delalle I, **Kesari S***. Pilocytic astrocytoma of the spinal cord in an adult. *Journal of Neuro-Oncology* 2008;88(2):189-91. PMID: 18340405

***Senior/corresponding author**

11. Drappatz J, Akar S, Fisher DC, Samuels MA, **Kesari S***. Imaging of Bing-Neel syndrome. *Neurology* 2008;70(16):1364. PMID: 18413593

***Senior/corresponding author**

12. **Kesari S***, Drappatz J, Akar S, Vergilio J, Wen PY, Soiffer RJ, Stone RM, DeAngelo DJ. Recurrent acute promyelocytic leukemia presenting as a sacral nerve root mass. *Journal of Clinical Oncology* 2008;26(19):3279-81. PMID: 18591563

***Senior/corresponding author**

13. Rasper M. **Kesari S***. Burkitt lymphoma presenting as a rapidly evolving cavernous sinus syndrome. *Archives of Neurology* 2008;65(12):1668. PMID: 19064758

***Senior/corresponding author**

14. Saad AG, Alyea EP 3rd, Wen PY, DeGirolami U, **Kesari S***. Graft-versus-host disease of the CNS after allogeneic bone marrow transplantation. *Journal of Clinical Oncology* 2009;27(30):e147-9. PMID: 19667266

***Senior/corresponding author**

15. Xia Z, Mehta BP, Ropper AH, **Kesari S***. Paraneoplastic limbic encephalitis presenting as a neurological emergency: a case report; *Journal of Medical Case Reports* 2010;4:95. PMID: 20334684

***Senior/corresponding author**

16. Housman E, Chang P, Lane SW, Blinder R, Galinsky I, **Kesari S**, Ho VT, Stone RM, Mullally A. CNS Relapse in Acute Promyelocytic Leukemia. *Journal of Clinical Oncology* 2010;28(24):e409-11. PMID: 20530270

17. Zhang M, Li F, Rasper M, Saad AG, **Kesari S***. Prolonged stability of progressive multifocal leukoencephalopathy in a patient with chronic lymphocytic leukemia. *Journal of Clinical Oncology* 2010;28(28):e503-6. PMID: 20585084

***Senior/corresponding author**

18. Pothiawala S, Hsu MY, Yang C, **Kesari S**, Ibrahim OA. Urticarial hypersensitivity reaction caused by temozolomide. *J Drugs Dermatology* 2010;9(9):1142-4. PMID: 20865848

19. Yavagal DR, Geng D, Akar S, Buonanno F, **Kesari S***. Superficial siderosis of the central nervous system due to bilateral jugular vein thrombosis. Arch Neurol 2010;67(10):1269-71. PMID: 20937957

***Senior/corresponding author**

20. Rosow L, Jiang JX, Deuel T, Lechpammer M, Zamani AA, Milner DA, Folkerth R, Marty FM, **Kesari S***. Cerebral phaeohyphomycosis caused by Bipolaris spicifera after heart transplantation. Transpl Infect Dis 2011;13(4):419-423. PMID: 21323827

***Senior/corresponding author**

21. Hu XQ, Imitola J, Kim RY, Mahta A, **Kesari S***. Brain metastasis from ovarian cancer: case report and review of the literature. Med Oncol 2012;29(2):1250-2. PMID: 21380785

***Senior/corresponding author**

22. Zhang M, Mahta A, Kim RY, Akar S, **Kesari S***. Durable remission of leptomeningeal metastases from hormone-responsive prostate cancer. Med Oncol 2012;29(2):806-8. PMID: 21424585

***Senior/corresponding author**

23. Hu A, Xu Z, Kim RY, Nguyen A, Lee JW, **Kesari S**. Seizure control: A secondary benefit of chemotherapeutic temozolomide in brain cancer patients. Epilepsy Res 2011;95(3):270-2. PMID: 21549564

24. Mahta A, Kim RY, **Kesari S***. Fourth ventricular choroid plexus papilloma. Med Oncol 2012;29(2):1285-6. PMID: 21630054

***Senior/corresponding author**

25. Moazzam AA, Drappatz J, Kim RY, **Kesari S***. Chronic lymphocytic leukemia with central nervous system involvement: report of two cases with a comprehensive literature review. Journal of Neuro-Oncology 2012;106(1):185-200. PMID: 21769650

***Senior/corresponding author**

26. Mahta A, Kim RY, Fanta PT, Lawson JD, **Kesari S***. Leptomeningeal metastasis from appendiceal adenocarcinoma: case report and literature review. Journal of Gastrointestinal Cancer 2011; (epub) PMID: 21826409

***Senior/corresponding author**

27. Duic JP, Grewal J, McConie K, Staszewski H, Haas J, **Kesari S***. Eltrombopag for radiation-induced thrombocytopenia in a glioblastoma patient. Journal of Neuro-Oncology 2012;106(2):427-9. PMID: 21833801

***Senior/corresponding author**

28. Zeng X, Mahta A, Kim RY, Saad AG, **Kesari S***. Refractory seizures due to a dural-based cavernoma masquerading as a meningioma. Neurol Sci 2012;33(2):441-3. PMID: 21918878

***Senior/corresponding author**

29. Mahta A, Qu, Y, Nastic D, Sundstrom M, Kim RY, Saria M, Santagata S, **Kesari S***. Relapsing tumefactive lesion in an adult with medulloblastoma previously treated with

chemoradiotherapy and stem cell transplant. *Pathol Oncol Res* 2012;18(2):539-43. PMID: 21953324

***Senior/corresponding author**

30. Mahta A, Kim RY, **Kesari S***. Progressive multifocal leukoencephalopathy with wallerian degeneration. *Eur Neurol* 2011;66(4):242. PMID: 21967919

***Senior/corresponding author**

31. Mahta A, Borys E, **Kesari S***. Cerebellar glioneuronal tumor: a case report and review of the literature. *Med Oncol* 2012;29(3):2038-9. PMID: 21993631

***Senior/corresponding author**

32. Qu Y, Davis JE, Chi J, **Kesari S***. 71-year-old female with right eye proptosis. *Brain Pathology*. 2011;21(6):709-10. PMID: 21995963

***Senior/corresponding author**

33. Mahta A, **Kesari S***. The blues of minocycline. *QJM* 2011; 106:77. PMID: 22052957

***Senior/corresponding author**

34. Mahta A, **Kesari S***. The greens of lead. *QJM* 2012;105(12):1223. PMID: 22052958

***Senior/corresponding author**

35. Mahta A, Borys E, Kanakamedala MR, **Kesari S***. Radiation induced myelopathy in a patient with tongue cancer. *Acta Oncol* 2012;51(3):409-11. PMID: 22060135

***Senior/corresponding author**

36. Mahta A, Kim RY, **Kesari S***. Levetiracetam-induced interstitial nephritis in a patient with glioma. *J Clin Neuroscience* 2012;19(1):177-8. PMID: 22071460

***Senior/corresponding author**

37. Li JC, Mahta A, Kim RY, Saria M, **Kesari S***. Cerebral syphilitic gumma: a case report and review of the literature. 2012;33(5):1179-81. PMID: 22167653

***Senior/corresponding author**

38. Cai P, Mahta A, Kim RY, **Kesari S***. Paraganglioma with intracranial metastasis: A case report and review of the literature. *Neurol Sci* 2012;33(5):1183-4. PMID: 22187335

***Senior/corresponding author**

39. Kanakamedala MR, Mahta A, Liu J, **Kesari S***. Late temporal lobe necrosis after conventional radiotherapy for carcinoma of maxillary sinus. *Med Oncol* 2012;29(4):2456-8. PMID: 22246565

***Senior/corresponding author**

40. Mahta A, Hu A, Kim RY, **Kesari S***. Decompensated chronic congenital hydrocephalus. 2011; 111(4):373. PMID: 22368987

***Senior/corresponding author**

41. Fan X, Mahta A, De Jager PL, **Kesari S***. Rituximab for tumefactive inflammatory demyelination: A case report. Clin Neurol Neurosurg 2012;114(10):1326-8. PMID: 22475882

***Senior/corresponding author**

42. Lin N, Huttner A, Spieler P, Claus EB, **Kesari S***. 55-year-old female with low back pain. Brain Pathology 2012;22(3):427-8. PMID: 22497615

***Senior/corresponding author**

43. Mahta A, Buhl R, Huang H, Jansen O, **Kesari S**, Ulmer S. Sellar and supra-sellar glioblastoma masquerading as a pituitary macroadenoma. Neurological Sciences 2013;34(4):605-7. PMID: 22569569

44. Imitola J, Pitt K, Peoples JL, Krynska B, Sheikh H, **Kesari S**, Azizi SA. Multifocal CNS infiltration of chronic lymphocytic leukemia in the form of small-cell solid metastatic disease. Journal of Neuro-Oncology 2012;109(1):213-15. PMID: 22573347

45. Rosenberg J, Mahta A, Koppula K, Borys E, **Kesari S***. Cyclophosphamide responsive primary angiitis of the CNS in a 61-year-old female. Clin Neuropath 2012;32(1):66-8 (**epub**) PMID: 23006473

***Senior/corresponding author**

46. Mahta A, Kim RY, Saad AG, **Kesari S***. 47-year-old man with left leg numbness. Brain Pathology 2013;23(2):223-4. PMID: 23432649

***Senior/corresponding author**

47. Srinivasan S, Mahta A, **Kesari S***. Cardioembolic stroke following a fractured transeptal wire. QJM 2012; (**epub**) PMID: 22645378

***Senior/corresponding author**

48. Mahta A, Du Z, Borys E, Carter B, Vandenberg SR, **Kesari S***. 78 year old male with dysphagia and dysarthria. Brain Pathology 2013;23(6):705-6. PMID: 24118489

***Senior/corresponding author**

49. Mahta A, Borys E, Vandenberg SR, Carter B, **Kesari S***. 72-year-old female with leg weakness. Brain Pathology 2014;24():195-6. PMID: 25121191

***Senior/corresponding author**

50. Van Vugt VA, Kesari A, Muller KA, Carter B, Vandenberg SR, **Kesari S***. A 22-year old woman with right eyelid swelling. Brain Pathology 2016 (**accepted**) PMID:

***Senior/corresponding author**

Letters to the Editor:

1. Meyer MA, Wen PY, **Kesari S**. Malignant Gliomas in Adults. New England Journal of Medicine 2008; 359(17): 1850

Educational Material:

2004	Neurology for Non-Neurologist	Course syllabus
2004	Intensive Review of Neurology	Course syllabus
2004	Society for Neuro-Oncology	Course syllabus
2005	Neurology for Non-Neurologist	Course syllabus
2005	Intensive Review of Neurology	Course syllabus
2005	Tumors of the Central Nervous System	Course syllabus
2006	Neurology for Non-Neurologist	Course syllabus
2006	Intensive Review of Neurology	Course syllabus
2006	Tumors of the Central Nervous System	Course syllabus
2011	Brain Tumors: 1 st Annual Collaborative Care Conference	Course syllabus
2011	Meningioma, American Brain Tumor Association	Brochure
2012	Brain Tumors: 2 nd Annual Collaborative Care Conference	Course syllabus

Thesis:

Kesari S. Viral therapy for central nervous system neoplasms: Studies using an ICP34.5 deficient herpes simplex virus in murine models [dissertation]. Philadelphia (PA): University of Pennsylvania; 1996.

Advisors: Nigel W. Fraser, John Q. Trojanowski, Virginia M.Y. Lee